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Introduction
Executive Summary
This report focuses on patent landscape analysis of technologies related to vaccines targeting
parasitic worms, also known as helminths. These technologies include methods of formulating
vaccines, methods of producing of subunits, the composition of complete vaccines, and other
technologies that have the potential to aid in a global response to this pathogen. The purpose of
this patent landscape study was to search, identify, and categorize patent documents that are
relevant to the development of vaccines that can efficiently promote the development of
protective immunity against helminths.
The search strategy used keywords which the team felt would be general enough to capture (or
“recall”) the majority of patent documents which were directed toward vaccines against
helminths. After extensive searching of patent literature databases, approximately 2847
publications were identified and collapsed to about 446 INPADOC families. Relevant patent
families, almost half of the total relevant families (210 being total number of relevant families),
were then identified and sorted into the categories of tremetodes, cestodes, nematodes or nonspecific helminth. The 210 patent families that were divided into these four major categories
were then further divided into sub categories relating to common fields of technology (e.g. DNA
vaccine, vaccine formulations, methods to produce subunits) This sorting process increased the
precision of the result set.
The four major categories (cestodes, nematodes, trematodes, and non specific applications) as
well as the overall data set of the 210 relevant family members were subjected to a range of
analytics in order to extract as much information as possible from the dataset. First, patent
landscape maps were generated to assess the accuracy of the sorting procedure and to reveal the
relationships between the various technologies that are involved in creating an effective vaccine.
Then, filings trends are analyzed for the overall dataset of the 210 relevant families as well as by
the categories of trematodes, cestodes, and nematodes. The country of origin each member of
the 210 relevant families was determined, and the range of distribution to other jurisdictions was
assessed. Filings were also analyzed by year, by assignee. Finally, the various patent
classification systems were mapped to find which particular classes tend to hold helminth
vaccine-related technologies. Besides the keywords developed during the searches and the
landscape map generation, the classifications represent an alternate way for further researchers to
identify emerging helminth vaccine technologies.
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ThemeScape map of terms from helminth vaccine patent documents. This category contained approximately 210
INPADOC patent families (analysis presented here is based on documents expanded from the 210 family members,
only 751 documents were accepted by the Themespace program). See Figure 21.

The analysis included creation of a map of keywords describing the relationship of the various
technologies involved in the development of helminth vaccines. The map has regions
corresponding to plasmids and other gene based technologies used in DNA vaccines for
Japonicum Schistosoma. Important technologies listed on the map include the use of reverse
genetics to create reassorted viruses targeted for the use in veterinary applications. Additionally,
the map suggests that numerous subunits exist for use in vaccines targeting cestodes, trematodes,
and nematodes.
Another major finding was that the number of patent documents related to helminths being
published has been steadily increasing in the last decade, as shown in the figure below. Until the
early-1990s, there were only a few helminth vaccine related patent documents being published
each year. The number of publications increased noticeably when TRIPS took effect, resulting
in publication of patent applications. However, since 2006 the number of vaccine publications
has exploded. In the years 2011 and 2012, about 23 references disclosing parasitic worm
vaccine technologies were published each year. Thus, interest in developing new and more
efficacious helminth vaccines has been growing in recent years.
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Publication trends for helminth vaccine documents. Publications increased in the 1990s when patent applications
began to be published. See Figure 26

The origin of the vaccine-related inventions was also analyzed. The team determined the
country in which the priority application was filed, which was taken as an indication of the
country where the invention was made or where the inventors intended to practice the invention.
By far, most of the relevant families originated with patent applications filed in the United States
and China. Other prominent priority countries were the United Kingdom, Japan, Brazil,
Australia and France. Countries with the most filings were also analyzed. Countries that were
heavily targeted for patent filings included the United States, Australia, Canada, and New
Zealand.
Top assignees for these families were mostly large pharmaceutical companies, with the majority
of patent families coming from Heska, followed by Merck & Co., Institut Pasteur, AusBiotech
Biotechnology, and Biological Sciences Research Council.
Lastly, the jurisdictions were inventors have sought protection for their vaccine technologies
were determined, and the number of patent families filing in a given country is plotted on the
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Jurisdictions for filing applications and issuing patents related to helminth vaccines. Filings in multi-jurisdictional
agencies, such as ARIPO, the Gulf Cooperation Council, WIPO and the European Patent Office, are not shown. The
number of patent families is out of 210 total families. See Figure 25 for a more detailed description.

world map shown (Fig. 25). The United States, Canada, Australia, Japan, New Zealand and
France have the highest level of filings, followed by Germany, Brazil, India, United Kingdom
and Spain. However, although there are a significant number of filings in Brazil, the remainder
of Central and South America has only sparse filings. Of concern, with the exception of South
Africa, few other African nations have a significant number of filings.
In summary, the goal of this report is to provide a knowledge resource for making informed
policy decisions and for creating strategic plans concerning the assembly of vaccines targeting
highly prevalent helminth infections. The ITTI team has defined the current state of the art of
technologies involved in the manufacture of helminth vaccines, and the important assignees,
inventors, and countries have been identified. This document should aid in evaluating the
current state of vaccines technologies targeting helminths and the potential outgrows of these
technological fields. Furthermore, as this report illustrates, the steady increase in helminth
patenting, expanded diversity of assignees and greater global filings, indicates that intellectual
property protection does not inhibit the development of crucial innovations for this class of
neglected diseases, but, on the contrary, appears to be a driver of accelerated research and
development.
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Disclaimer
This educational report is neither inclusive nor comprehensive. Rather, it is an informational
resource intended to facilitate a better understanding of the international patent literature
landscape regarding vaccines against helminths.
This report is not a list of all potentially relevant patents. Importantly, it is not a Freedom to
Operate (FTO) opinion, but instead constitutes an educational analysis of potentially relevant
material. While the search platforms utilized in this project were extensive, none were
comprehensive, and some countries and jurisdictions were underrepresented in the databases,
either in the time frame covered, the availability of translated documents, and the completeness
of the records. Further, it is likely that the International Technology Transfer Institute (ITTI)
team did not obtain the entire spectrum of relevant patents utilizing the various search strategies
and methods articulated herein. Therefore, the ITTI team does not guarantee that all relevant
patents were discovered during the creation of this report.
As the ITTI team members are not experts in the field of helminth related vaccines and related
technologies, it is likely that the categorization of the patents found and coded are incomplete.
Further, many patent documents contain material relevant to multiple categories; the documents
were placed in the category that the team, in its judgment, felt best represented the overall focus
of the document. The ITTI team cannot guarantee that the patents discovered were evaluated at
the level of expert scientific sophistication.
The limited time frame, competing academic demands, and the general press of business dictated
the number of patents evaluated. As such, additional patents may have been available that were
not considered due to time constraints.
Many names are capitalized and may or may not be trademarked and/or otherwise protected
intellectual property. The team apologizes for any errors or mistaken omissions.
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Abbreviations and Definitions
Below is a list of abbreviations and definitions for terms and keywords used throughout the ITTI
Fall 2012 report and the reported results.
Adjuvants – defined herein as a substance sometimes included in a vaccine formulation to
enhance or modify the immune-stimulating properties of a vaccine.1
Antibody – defined herein as an infection-fighting protein molecule in blood or secretory fluids
that tags, neutralizes, and helps destroy pathogenic microorganisms (e.g., bacteria, viruses) or
toxins. Antibodies, known generally as immunoglobulins, are made and secreted by Blymphocytes in response to stimulation by antigens. Each specific antibody binds only to the
specific antigen that stimulated its production.2
Antibody-mediated immunity – defined herein as the immunity that results from the activity of
antibodies in blood and lymphoid tissue (also called humoral immunity).3
Antigens - (immunogens; substances capable of provoking an immune response) – defined
herein as foreign substances in the body that are capable of causing disease. The presence of
antigens in the body triggers an immune response, usually the production of antibodies.
Antigens may be soluble substances, such as toxins and foreign proteins, or particulate, such as
bacteria and tissue cells; however only the portion of the protein of polysaccharide molecule
known as the antigenic determinant combines with antibody or a specific receptor on a
lymphocyte.4
Anti-idiotype - herein defined as a manufactured antibody (Ab2) that can recognize the idiotype
of another antibody (Ab1). Theoretically, the anti-idiotype antibody mimics the structure of the
antigen recognized by Ab1. When Ab2 is injected into the host, the host develops
immunological memory comprising antibodies (Ab3) which have similar specificities as Ab1.5

B cells – defined herein as small white blood cells that help the body defend itself against
infection. These cells are produced in bone marrow and develop into plasma cells that produce
antibodies. These cells are also known as B-lymphocytes.6

1

American Heritage Dictionary definition: http://education.yahoo.com/reference/dictionary/entry/adjuvant.
http://medical-dictionary.thefreedictionary.com/antibody.
3
http://medical-dictionary.thefreedictionary.com/humoral+immunity.
4
http://medical-dictionary.thefreedictionary.com/antigen.
5
http://en.wikipedia.org/wiki/Anti-idiotypic_vaccine.
6
http://en.wikipedia.org/wiki/B_cell.
2
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BLAST – defined herein as the acronym for Basic Local Alignment Search Tool. This
program compares nucleotide or protein sequences to sequence databases and calculates the
statistical significance of matches.
Booster – defined herein as a second or later vaccine dose given after the primary dose(s) to
increase the immune response to the original vaccine antigen(s). The vaccine given as the
booster dose may or may not be the same as the primary vaccine.7
Cestode- defined herein as a member of the phyla Platyhelminths. Commonly known as a
tapeworm. Also a member of the group called helminths.8
Delivery Systems – defined herein as a method or system by which a vaccine is delivered to the
host body.9
DNA (deoxyribonucleic acid) - defined herein as the double-stranded, helical molecular chain
found within the nucleus of each cell. DNA carries the genetic information that encodes proteins
and enables cells to reproduce and perform their functions.10
DNA vaccine (nucleic acid vaccine) - defined herein as direct injection of a gene(s) coding for a
specific antigenic protein(s), resulting in direct production of such antigen(s) within the vaccine
recipient in order to trigger an appropriate immune response.11
DWPI – defined herein as Derwent World Patent Index, which is the world’s most
comprehensive database of patent documents. DWPI includes over 20 million patent document
families, which covers over 42.5 million patent documents. The DWPI database includes
coverage from over 44 worldwide patent authorities.12
Efficacy - defined herein in vaccine research, the ability of a vaccine to produce a desired
clinical effect, such as protection against a specific infection or disease, at the optimal dosage
and schedule in a given population. A vaccine may be tested for efficacy in Phase 3 clinical
trials if it appears to be safe in Phase 1 trials and has shown efficacy at certain dosages in Phase 2
trials.13

7

http://en.wikipedia.org/wiki/Booster_dose.
http://en.wikipedia.org/wiki/Cestoda
9
Crystal Chan, et. al., Advancing Adjuvants and Vaccine Delivery Systems for Better Vaccination Strategies,
BioPharm Int’l Supplements, Jan. 2, 2010.
10
http://education.yahoo.com/reference/dictionary/entry/DNA.
11
http://www.who.int/biologicals/areas/vaccines/dna/en/index.html. See also http://www.dnavaccine.com/.
12
http://thomsonreuters.com/products_services/legal/legal_products/a-z/derwent_world_patents_index/.
13
http://en.wikipedia.org/wiki/Vaccine_efficacy.
8
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Epitope - defined herein as a specific site on an antigen that stimulates specific immune
responses, such as the production of antibodies or activation of immune cells.14
Expression system - defined herein as in genetic engineering, the cells into which a gene has
been inserted into a host cell in order to manufacture desired proteins.15
Functional antibody - defined herein as an antibody that binds to an antigen and has an effect
that can be demonstrated in laboratory tests.16
Gene – defined herein as a unit of genetic material (DNA); a segment of DNA encoding a
protein molecule; a segment of DNA that contains the information for a specific function.17
Helminth- defined herein as a parasitic worm belonging to phylum nematoda or phylum
platyhelminthies.18
Host - defined herein as a plant or animal harboring another organism or a pharmaceutical
composition.19
Immune system - defined herein as the complex system (network of specialized cells and
organs) in the host body responsible for fighting and responding to disease (immune response).
Its primary function is to identify foreign substances (antigens of bacteria, viruses, fungi, or
parasites) in the body and develop a defense against them. It involves production of proteins
called antibodies to eliminate these foreign organisms that have invaded the host, and the
generation of cytotoxic activity to eliminate infected cells.20
Immunity - defined herein as a natural or acquired resistance provided by the immune system to
a specific disease. Immunity may be partial or complete, specific or nonspecific, long lasting or
temporary. Immunity is indicated by the presence of antibodies and antigen-reactive cells in the
blood and can usually be determined with a laboratory test.21
Immunization - defined herein as the process by which a person or animal becomes protected
against a disease; the process of inducing immunity by administering an antigen (vaccine) to

14

http://medical-dictionary.thefreedictionary.com/epitope.
http://www.news-medical.net/health/Gene-Expression-System.aspx.
16
http://en.wikipedia.org/wiki/Antibody.
17
http://en.wikipedia.org/wiki/Gene.
18
http://www.who.int/topics/helminthiasis/en/; see also, http://www.phsource.us/PH/PARA/Chapter_4.htm
19
http://en.wikipedia.org/wiki/Host_%28biology%29.
20
http://en.wikipedia.org/wiki/Immune_system.
21
http://medical-dictionary.thefreedictionary.com/immunity.
15
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allow the immune system to prevent infection or illness when it subsequently encounters the
infectious agent. This term is often used interchangeably with vaccination or inoculation.22
INPADOC (International Patent Document Center) – defined herein as a patent database
maintained by the European Patent Office (EPO).23
ITTI – defined herein as International Technology Transfer Institute, an intellectual
property clinic at the University of New Hampshire School of Law.24
NCBI – defined herein as the acronym for National Center for Biotechnology
Information. NCBI provides access to biomedical and genomic resources, such as BLAST.25
Nematode- defined herein as a member of the phylum nematoda, common specimens of
nematodes include roundworms, whipworms, and threadworms.26
Parasitic Worm- defined herein as a member of the phyla Nematoda or plathyhelminthies. Also
known as a helminth.
Passive immunization – defined herein as the introduction of antibodies or antiserum into a host
to treat an infection, wherein such treatment does not result in immunological memory and longlasting immunity in the host.27
Patent document count – defined herein as an expanded patent family which includes all issued
patents and patent applications that fall within that family.
Patent family – defined herein as a group of patent documents having a commonality such as
priority document (INPADOC) or claimed invention (DWPI). The patent documents can be
from any jurisdiction.
PCT – defined herein as the Patent Cooperation Treaty, which is an international treaty
whose goal is to provide a unified procedure for filing patent applications in the contracting
states. A contracting state is a country which has signed onto the treaty. A patent application
filed under the PCT is commonly referred to as an international application, or PCT
application.28
22

http://www.who.int/topics/immunization/en/.
http://www.epo.org/searching/essentials/patent-families/inpadoc.html.
24
http://law.unh.edu/franklin-pierce-ip-center/international-technology-transfer-institute.
25
http://www.ncbi.nlm.nih.gov/.
26
http://en.wikipedia.org/wiki/Nematode
27
http://en.wikipedia.org/wiki/Passive_immunity.
28
http://www.wipo.int/pct/en/texts/articles/atoc.htm.
23
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Pharmaceutical Compositions – defined herein as the combination of distinct parts or elements
to form a whole relating to pharmacy, drugs, or medicine. This can include anything from
vitamins, antibodies, antigens, medicaments, and adjuvants.
Trematoda- defined herein as a subphyla of phylum platyhelminthies. This phylum contains one
of the most commonly known helminth, liver flukes.29
Vaccine - defined herein as a preparation that stimulates an immune response that can prevent an
infection or create resistance to an infection based upon an antibody response to an antigen.30
Veterinary Vaccines- herein defined as vaccines targeting helminths for the specific use in nonhuman animals. Target animals include fowl (chicken, ducks, geese, etc.), pigs, horses, and
dogs.31

29

http://en.wikipedia.org/wiki/Trematode
http://en.wikipedia.org/wiki/Vaccine.
31
http://www.ott.nih.gov/Technologies/abstractDetails.aspx?RefNo=1731.
30
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Background of the Technology
Parasitic worms, also known as helminths are worm-like organisms that live in and feed
on living hosts. These parasitic worms are multicellular
organisms that are generally visible to the naked eye in their
adult stages.32 Parasitic worms general fall into three different
phyla: plathyhelminthies or flatworms, acanthocephia or thorny
headed worms, and nematoda or roundworms.33 This report
focuses on parasitic worms that are from the phyla nematoda and
platyhelminths and not those from the phyla acanthocephia.
The phylum plathyhelminths, also known as flatworms, is
a diverse phylum that contains cestodes (tapeworms), trematodes
(flukes) and tubellaria. The class tubellaria will not be included
in this report as they do not infect humans. The term cestode is
derived from the Latin word cestus, which means "tape". The
adult forms of all 3,400 species of cestodes are internal parasites
in the organs of vertebrates, including fish, cats, dogs and
humans.34 Cestodes have no mouths as their syncitial skin
absorbs nutrients from their host. This syncitium also disguises
these nutrients chemically chemically to avoid attacks by the
host's immune system.35
Class trematoda, individuals of this class known as
trematodes, contains the organism known as flukes, one of the most well
Figure 1. An image depicting
phyla nematoda and
known and most prevalent helminths to infect humans.36 The term
platyhelminthies relationship
trematoda refers to the cavities in their holdfasts, which resemble a
to other phyla.
sucker of leech, and anchors them within their host.37 The skin of all
trematodes is composed of a syncitium, a layer of cells that shares a
single external membrane. The class trematoda contains more than 11,000 unique species,
making it one of the most prevalent types of parasitic worms on earth.
The last phyla of interest is nematoda, members of this phylum are also known as
roundworms. Phylum nematoda is one of the largest groups of animals as over two thousand
eight hundred species are contained in this phylum38 Species from phylum nematoda inhabit
32

Maizels RM, Yazdanbakhsh M, "Immune regulation by helminth parasites: cellular and molecular
mechanisms". Nat. Rev. Immunol. 3 (9): 733–44. (2003)
33
Ibid
34
Ruppert, E.E., Fox, R.S., and Barnes, R.D. (2004).Invertebrate Zoology (7 ed.). Brooks / Cole. pp. 226–269.
35
Ibid
36
Ibid.
37
Ibid.
38
Hugot J-P, Baujard P, Morand S (2001). "Biodiversity in helminths and nematodes as a field of study: an
overview". Nematology 3 (3): 199–208
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almost every ecosystem known to man.39 Nematodes vary greatly in size as some may be as long
as 5cm while others may be microscopic in size.40 Unlike the group platyhelminthies, nematodes
outer covering may be either a syncitum or a thick nonliving cuticle layer.41

Helminth Life Cycles, Diseases, and Epidemiology
Approximately one billion people in the poor, developing regions of sub-Saharan Africa,
Asia, and the Americas are infected with one or more parasitic helminth. 42 The most common
helminth diseases are caused by an infection from soil-transmitted nematodes (e.g. the
roundworm), filarial worms, flukes, or tapeworms (See Table 1). Many of the people living in
poor rural villages in the tropics and subtropics are often chronically infected with several
different species of parasitic worm, commonly referred to as “polyparasitized”.43 Note that the
above table is from 2008 and that the prevalence for some helminths have decreased and
increased remarkably. More accurate statistics will be further reflected in the report.

Figure 2. Major human helminthiases and their global prevalence and distribution44

39

Borgonie G, García-Moyano A, Litthauer D, Bert W, Bester A, van Heerden E, Möller C, Erasmus M, Onstott
TC (June 2011). "Nematoda from the terrestrial deep subsurface of South Africa". Nature 474 (7349): 79–82.
40
Ruppert EE, Fox RS, Barnes RD (2004). Invertebrate Zoology (7th ed.). Brooks/Cole.
41
Ibid.
42
Hotez, Peter, Paul Brindley, Jeffrey Bethony, Charles King, Edward Pearce, and Julie Jacobson. "Helminth
infections: the great neglected tropical diseases." The Journal of Clinical Investigation 118, no. 4 (2008): 1311.
43
Ibid.
44
Ibid. at 1312.
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There are four primary modes of helminth transmission: soil-borne, foodborne, waterborne, and insect-borne. Most of the diseases WHO determined neglected tropical diseases are
soil-borne.45 Environmental factors, such as warm, moist climates and poor sanitation and
hygiene, make tropical areas the perfect habitat for soil-borne helminths, however, many species
may survive in temperate climes, as well, especially during the summer. In Latin America and
the Caribbean, soil-transmitted helminths are present in all countries with an estimated 26.3
million school-age children at risk of infection. In 13 of the 14 countries in this region, many
areas have infection prevalence higher than 20%. Globally, approximately 300 million people
suffer from severe morbidity that results in 10,000–135,000 deaths annually. However, their
greatest impact is through the impairment of physical and mental development in children, which
ultimately retards educational advancement and economic productivity. 46
A study of detailed description of the global limits for Ascaris lumbricoides, Trichuris
trichiura, and the hookworms Ancylostoma duodenale and Necator americanus using surveys of
infection prevalence derived from the Global Atlas of Helminth Infection.47 Figure 1 shows the
transition stability of soil-transmitted helminths (excluding some countries on the basis of
socioeconomic status).

Figure 3. Distribution of soil-transmitted helminth indicating areas at stable risk of transmission in 201048

Based on factors such as climatic and socio-demographic indicators, human population
density and settlement patterns, it was estimated that “5.08 billion people (1.0 billion of schoolgoing age) live in areas of stable hookworm transmission worldwide, 22% located in Africa and
45

World Health Organization. "Neglected Tropical Diseases." WHO Programmes and Projects.
www.who.int/neglected_diseases/diseases/en/ (accessed February 25, 2013).
46
Ibid.
47
Pullan, Rachel, and Simon Brooker. "The global limits and population at risk of soil-transmitted helminth
infections in 2010." Parasites and Vectors 5, no. 81 (2012): 2.
48
Ibid. at 11.
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the Middle East, 69% in Asia and 9% in Latin America and the Caribbean”.49
Generally, soil-borne worm eggs or juveniles contaminate soil via animal and human
defecation or the use of feces containing such eggs or juveniles as fertilizer for produce. The
eggs are ingested via contaminated produce or by placing fingers or other objects that have come
into contact with contaminated soil into one’s mouth. Usually there is no vector which the egg
or juvenile must pass through and mature in before infecting the terminal host.
Because most soil-borne worms primarily infect the small and large intestine, individuals
parasitized by different species of these worms often present with a similar set of gastrointestinal
symptoms.
Ascaris lumbricoides is one of the most
prevalent of the prevalent, accounting for a large
percentage of the global parasitic worm burden.50
The CDC estimates that 807-1,221 million people
worldwide are infected by this species. The
ascarid lifecycle is unique from other soil-borne
worms in that the larvae must mature in the lungs.
Eggs are ingested and hatch in the gastrointestinal
tract from which they burrow through the mucosa
to the portal veins leading to alveoli and
pulmonary vascular capillary beds.51 The larvae
cause lung irritation which results in the host
coughing the larvae up into the oral cavity where
they are swallowed back down into the GI tract.
52
The female can release 200,000 eggs each day.
Adults live for a year or two.
Figure 4. Lifecycle of A. Lumbricoides
Ascariasis is more burdensome for children, and can be transmitted to a fetus
transplacentally. Annually, there are 8-100,000, most of which are children with obstructed or
perforated bowels. Along with the GI symptoms common to all intestinal worms, ascariasis can
also present with wheezing, intestinal blockage, tingling throat, appendicitis, pancreatitis, and
impaired growth in children.53
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Hookworms are estimated to infect
between 760 million-1.3 billion people
worldwide.54 Two main species,
Anclostoma duodenale and Necator
americanus, are responsible for the
global worm burden. Hookworm
infection is widespread throughout the
tropics and subtropics. N. americanus is
the most prevalent hookworm, being
found throughout sub-Saharan Africa,
tropical regions of the Americas, south
China, and Southeast Asia while A.
duodenale is spreading in parts of India,
China, Africa, and parts of the Americas.55
Figure 5. Lifecycle of the hookworm
The eggs of these species are not infectious. The eggs are released into the soil in feces,
where they mature into larvae. Unlike other soil-borne helminths, an individual becomes infected
when a larva penetrates one’s bare feet. A. duodenale larvae are infectious if ingested, while this
is not the case for N. americanus.
Ancylostomiasis is often symptomless if the parasite burden is low. A higher burden
presents with anemia and fatigue, along with GI symptoms. Because children and women of
reproductive age have reduced iron reserves, both are at particular risk. In children, anemia and
protein malnutrition resulting from chronic intestinal parasitism can cause impairment in
physical, intellectual, and cognitive development. In pregnant women, severe iron deficiency
anemia arising from hookworm disease can result in additional health risks for the mother and
fetus or newborn. 56
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Figure 6. Prevalence of hookworm infection worldwide 57

Food-borne helminths are transmitted through ingestion of undercooked meat (including
fish, mammals, and mollusks), raw
aquatic plants, and raw vegetables
contaminated by fecal matter. Poor
hygiene, unsanitary food preparation
and undercooking are the leading
factors of transmission. Diseases caused
by foodborne helminths have common
symptoms: abdominal pain, diarrhea,
muscle pain, cough, lesions,
malnutrition, weight loss, and
neurological deficiencies.58
Trichinella spiralis is a
nematode that requires two intermediate
hosts. The worm initially infects a
rodent, which is then eaten by a pig or
another carnivore. A human ingests
undercooked pork containing encysted
larvae. Encysting allows the larvae to
Figure 7. Lifecycle of T. spiralis
remain dormant for years while waiting
57
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to be transmitted to a terminal host. Gastric acid and pepsin in the host stomach degrade the cyst
and allow the release of the larva. The larvae mature in the small intestine, where they live for
about 4 months.59
Trichinella can be found in almost every corner of the world. Other species of Trichinella
infect different hosts and may also infect humans. T. pseudospirals infects mammals and birds,
however, it does not encyst in the striated muscle like T. spiralis. T. native infects arctic bears. T.
nelson infects African predators and scavengers. T. brivovi
infects European and Asian carivores.60
The severity of the symptoms of trichinellosis (or trichinosis) is correlated to the worm
burden of the afflicted host. If the burden
is low, the host may be asymptomatic or
presenting with mild gastric symptoms
like nausea and diarrhea. Mild cases tend
to mirror the flu and clear up on their own
within a few months. Severe infection can
result in difficulty coordinating
movements, cardiac and pulmonary
problems, and even death.61
Diphyllobothrium is transmitted
through fish and is found in Europe, Asia,
Russia, North America, Uganda, and
Chile. This tapeworm has become an
increasingly global problem as infected
Figure 8. Lifecycle of Diphyllobothrium

fish are sold on the world market. Luckily, this tapeworm is killed by properly cooking or
freezing the infected fish. Fish become infected after eating an infected copepod. The mature
adults live in the small intestine of humans. A female has over 3, 000 gravid proglottids-where
each proglottid is capable of releasing huge numbers of eggs-resulting in around a million eggs
released per worm each day. There are several species of Diphyllobothrium. D. latum is the
largest and can grow up to 30 feet in length.62
Diphyllobothriasis is usually asymptomatic and can go years without detection. In severe
cases, the host may suffer intestinal obstruction, gall bladder disease caused by migrating
proglottids, the common GI symptoms noted above. Severe vitamin B12 deficiency may occur
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after years of infection, as the parasite absorbs approximately 80% of the hosts B12. Subacute
degeneration of the spinal cord also occurs in more severe cases.63
Taenia sp. are cestodes found in Latin
America, Asia, and Africa.64 Some of the
prevalence of this parasite in developed
countries is because of immigration from and
tourism. 65Humans are their only terminal host.
Cows are the vectors for T. saginata. Pigs are
the vectors for T. solium. Poor sanitation and
improper food preparation lead to human
infection when humans eat undercooked
contaminated pork or beef. Gravid proglottids
containing eggs are released in feces and
remain infective for months in moist
environments. Cattle and pigs are infected after
eating contaminated vegetation. Oncospheres
hatch from the eggs in the vector’s
Figure 9. Lifecycle of Taenia
intestine. The oncospheres invade the intestinal wall and migrate to the striated muscle where
they encyst as cysticerci, which can survive dormant for years. A human eats this undercooked
meat. Adults attach to the small intestine. Six gravid proglottids are released in feces each day,
with each proglottid containing hundreds of thousands of eggs.66
Taeniasis can be asymptomatic when acute. T. saginata tends to be more symptomatic
than T. solium. In more serious infections the host experiences abdominal pain, appetite loss,
weight loss, upset stomach. Proglottids may get stuck in appendix, or in the biliary or pancreatic
ducts. T. solium can cause cysticercosis, an infection of the brain, muscle and other tissues by
cystircerci. Symptoms include seizures, muscle and eye damage. 67
Flukes are a type of trematode that infect 56 million people in 70 countries. All members
of this group have similar life cycles, with the exception of schistosomes, which will be covered
in waterborne worms below.
Clonorchis sinensis is a liver fluke found primarily in Asia. It infects does and fish eating
carnivores. Eggs are released with feces. They require freshwater to develop into cercaria. The
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cercaria is eaten by a snail, where it matures into a metacercaria. The metacercaria leaves the
snail and penetrates a fish, encysting in the subcutaneous tissue. That fish is eaten by a carnivore.
The metacercaria is released from the cyst in the host’s intestine, whence it migrates to the bile
ducts.68
Clonorchiasis affects 12.5
million people in China alone. An
acute infection may be asymptomatic.
More severe infections cause fever,
pain in the upper right quadrant, colon
pain, gall bladder obstruction.
Chronic infection destroys the liver
parenchyma and causes inflammation
of the walls of the bile ducts, resulting
in fibrosis. Fibrosis of the bile ducts
puts the host at risk for
cholangiocarinoma, which is severe
and often fatal bile duct cancer.69
Figure10 . Lifecycle of the Fluke.

Fasciola hepatica and Fasciola gigantica are local to Europe, the Americas, Oceania and
especially the South American highlands. Greater incidences of infection are found along trade
routes of the host plants, watercress and water mint. Other hotspots for infection include the Nile
valley, Caspian Sea basin, as well as East and Southeast Asia. 2.4 million People are infected in
over 70 countries. The worms contaminate a freshwater source when an infected animal
defecates in or near that source. Cercariae hatch from the eggs and penetrate snails. The cercariae
mature into metacercariae and leave the snail. The metacercariae affix themselves to an aquatic
plant and form metacercarial cysts. Humans are infected either by eating the plant or an animal
that has eaten the plant, or by imbibing water with free floating metacercarial cysts. In the human
host, metacercariae penetrate the intestinal wall and peritoneum to get to the liver, which they
burrow through on their way to the bile ducts. Metacercariae mature into adults in the bile ducts
and then release eggs into the bile which flows to the intestine and out with feces.70
Fascioliasis is asymptomatic in the acute phase. After two to four months, the host suffers
internal bleeding (due to migration of the metacercaria), fever, nausea, swollen liver, skin rashes,
and severe abdominal pain. Once the metacercariae reach the bile ducts the host suffers

68

"CDC - Clonorchis - Biology." Centers for Disease Control and Prevention.
http://www.cdc.gov/parasites/clonorchis/biology.html (accessed May 9, 2013).
69
World Health Organization. "Clonorchiasis." Foodborne Trematode Infection.
www.who.int/foodborne_trematode_infections/clonorchiasis/en/ (accessed February 25, 2013).
70
World Health Organization. "Fascioliasis." Foodborne Trematode Infection.
www.who.int/foodborne_trematode_infections/clonorchiasis/en/ (accessed February 25, 2013).

23

intermittent pain, jaundice, anemia, pancreatitis, gallstones, and liver fibrosis due to prolonged
inflammation. Secondary infection often occurs.71
Waterborne helminths are transmitted through contact with water either via imbibition or
physical contact.72
Drancunculus medinensis, or the
Guinea worm, is transmitted to humans
when a human drinks water containing
infected copepods. The copepods die in the
GI tract and release larvae. The larvae
penetrate the host’s stomach or intestinal
wall and migrate to the abdominal cavity and
retroperitoneal space, where they mature into
adults. After copulating the male dies and the
female migrates to the subcutaneous tissue of
a lower extremity. After a year of living in
the subcutaneous tissue, a blister forms
around the worm. When the blister ruptures,
the female emerges and releases larvae upon
contact with water. Those larvae are eaten by
Figure 11. Lifecycle of the Guinea Worm
copepod, in which they molt twice before
becoming infective to humans.73
A human with dracunculiasis, or Guinea worm disease, remains asymptomatic for
approximately a year while the worm is maturing, mating, and migrating.74Once the worm is
ready to release larvae, the host may suffer from blisters, ulcers and edema which cause a
burning pain that the host tries to alleviate by dipping the lesion in cool water.75 These symptoms
are accompanied by itchy rashes, fever, nausea, vomiting, diarrhea, and dizziness.76 It is common
for the host to suffer secondary infection due to exposure of lesion. In that case, the host may
suffer cellulitis (redness and swelling of the skin), abscesses, sepsis, septic arthritis-infections of
the joints that may lead to deformation of the joints, and tetanus. The disease is treated by
wrapping the worm around a rod and turning that rod a little bit every day to remove the worm
without breaking it. Breaking the worm causes inflammation and painful cellulitis where the
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worm degrades. This disease causes lack of mobility for 2 months or more and can cause
permanent disability in children.77
The number of new cases of dracunculiasis occurring worldwide each year has decreased
from an estimated 3.5 million to 1,058 since the 1986 World Health Assembly, the decisionmaking body of the World Health Organization, declared global elimination as a goal.78 The
number of dracunculiasis cases reported worldwide in 2011 declined by 41%, compared with
2010, and by 51% from January–June 2011 to January–June 2012. Transmission remains
endemic in four countries, with just one, South Sudan, accounting for 99% of all reported cases
during January–June 2012.79

Figure 12. Geographical distribution of co-infections with helminth infections. Infections include: lymphatic
filariasis (LF), onchocerciasis (Oncho), schistosomiasis (SCH), and soil-transmitted helminthiases (STH). 80
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Schistosomes are known as the blood flukes.81 This trematode is the cause of widespread
infection in 76 countries and territories. Schistosoma mansoni is endemic in 54 countries and S.
haematobium in 55. Infection by S. japonicum remains an important public health burden in the
Philippines, China, and parts of Indonesia, despite the program controls taking place. Almost 800
million individuals are at risk across the globe; about 200 million people are infected. Of the 200
million people infected with Schistosoma spp. in the world, 160 live in SSA, where
approximately 110 million are infected with S. haematobium. Schistosomiasis causes “15,000–
280,000 deaths annually in SSA alone and severe disability in approximately 20 million
people”.82
Schistosome eggs are passed in feces or urine and hatch in water. The larvae penetrate a
snail in which they mature into an infective stage larvae. These infective larvae are released back
into the water, where they can survive for up to two days while waiting to encounter a host.
When a human steps into the
contaminated water the
schistosome larva penetrates
the skin on the individual’s
foot. From the foot the larva
migrates through the tissues
to the veins.83 Adults live in
the mesenteric venules
emptying into the unrinary
tract, intestine and
abdominal cavity. Eggs often
get trapped in the body
causing tissue damage.84
Schistosomiasis is
known in some parts of the
world as bilharzia. The host
is initially asymptomatic. A
few days after infection the
host develops an itchy rash.
After a month or two fever,
Figure 13. Lifecycle of a Schistosome
chills, cough and muscle ache set in. Years of infection causes damage to the liver, intestine,
spleen, lungs and bladder. 200,000 cases a year result in death in sub-Saharan Africa. There are
two types of schistosomiasis: intestinal and urogenital. Intestinal schistosomiasis causes
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abdominal pain, enlarged liver, bloody stool, diarrhea and enlarged spleen. Urogential
schistosomiasis causes difficulty urinating, heightened risk of bladder cancer, bloody urine,
infertility and bladder and ureteral fibrosis. Urogenital schistosomiasis can cause infertility in
both men and women. Women may suffer from lesions on the cervix or vagina, vaginal bleeding,
nodules on the vulva, and pain during intercourse. Men may suffer damage to the seminal
vesicles and prostate. Eggs released by schistosomes that inadvertently migrate to the brain or
spinal cord cause seizures, paralysis and inflammation of the spinal cord. Children are especially
susceptible to anemia, malnutrition and learning disabilities. Different species are correlated with
certain types of cancer and fibrosis.85
Insect-borne are transmitted to humans when the insect-vector bites a human.
Onchocerca volvulus is prevalent in fertile riverside areas where Simulium blackflies live. An
infected fly bites a human, passing the larvae to the subcutaneous tissue. The larva creates a
nodule, where it matures into an adult. The female releases around 1,000 juveniles a day. The
juveniles migrate to the subepidermal tissue so that they may be transmitted to a fly when the
human is bitten.86
Onchocerciasis, also known as River Blindness, has rendered around half a million
people blind and is the leading cause of blindness in west and central Africa. The disease is also
prevalent in 6 Latin American countries. Presently, it is estimated that 37 million people carry O.
volvulus, with 90 million at risk in Africa. Morbidity at present is estimated at 987,000 disabilityadjusted life-years and there are 46,000 new cases of blindness annually.87 See Figure 13.
Onchocerciasis causes skin rashes and lesions, intense itching and depigmentation, as
well as optical symptoms. The eye may be inflicted with bleeding, lesions and inflammation.
Every part of the eye is subject to infection, except the lens, however the lens may still become
inflamed. These symptoms cause blindness.88
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Figure 14. World distribution of onchocerciasis89

Wucheria bancrofti is transmitted through mosquito bites. The larva migrate to lymphatic
vessels after transmission and mature into adults.90 The resulting disease is lymphatic filariasis,
which is endemic in 83 countries and territories. It is
estimated that 1.3 billion people are at risk for
developing the disease, with some 120 million people
being infected. Over 40 million people are seriously
incapacitated and disfigured by the disease. Of these,
95% are infected with Wuchereria bancrofti, and the
remainder with Brugia malayi or Brugia timori. The
infection, usually acquired in early childhood, causes
considerable morbidity and social stigma because of
the deformities it produces.91. Lymphedema, or
pooling of lymphatic fluid in the extremities, occurs in
the early stages of this disease. Late stage lymphatic
filariasis results in elephantiasis.92
Figure 15. Lifecycle of W. bancrofti
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Types of Vaccines
The types of vaccines encountered are divided into protein subunit vaccines and DNA
vaccines. Protein vaccines formed by introducing a fragment of microorganism to the immune
system to create an immune response.93 Examples include the subunit vaccine against Hepatitis
B virus that is composed of only the surface proteins of the virus.94
DNA vaccines employ modified DNA that is injected into the cells of the body, where
the "inner machinery" of the host cells "reads" the DNA and uses it to synthesize the pathogen's
proteins.95 Because these proteins are recognized as foreign, when they are processed by the
host cells and displayed on their surface, the immune system is alerted, which then triggers a
range of immune responses.96

Figure 16. Production of recombinant viruses in cell lines (this image is used to
fundamental principles of recombinant DNA molecular biology)
).
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Advances in Helminth Vaccines
The emergence of drug resistant parasites and the limited sustainability of drug
administration programs in endemic areas have provided great incentive for the development of
molecular vaccines for helminth infections.97 Vaccines targeting particular proteases produced
by helminths represent an area of which the most success in helminth vaccinology has been
achieved. 98
Additionally, endeavors into vaccines targeting infective helminth larvae are increasingly
common as the adult stage of many problematic helminths are not only drug resistant but also
less susceptible to type II immune responses.99
Potential Advantages of Vaccination.
The current method of mass treatment for helminth infections is through a deworming
campaign where the worm is either physically removed or removed by providing the infected
with medication.100 The cost of mass deworm is little, roughly estimated at $0.25USD per child
under WHO’s current treatment plan.101 While cost of removing helminths by medication is low,
this style of treatment needs to be performed twice to three times yearly in areas with medium or
high prevalence of infection.102 Additionally, deworming by medication does little to prevent
rapid reinfection of a parasite.103 It is for this reason that a vaccine targeting helminths may be a
more desirable form of treatment as a vaccine would likely prevent reinfection and require far
fewer deworming campaigns as the immunity would likely stay with the inoculated for a much
longer period of time.

Scope of the Project
The ITTI team began this project by setting the goal for the team to produce a patent landscape
report surveying the technologies necessary to produce a vaccine targeted parasitic worms that
infect humans. The ITTI team then needed to limit the scope of the project in both the types of
technologies to be surveys and the types of organizes to be surveyed. The ITTI team set the
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scope of the project to include the following: all types of complete vaccines, veterinary vaccines,
methods of vaccine production and formulation, methods of producing subunits useful for
vaccines, and general platforms related to parasitic worm vaccines. In addition, the ITTI team
decided the scope of the project would include all species of parasitic worms that fall under the
phyla nematoda or platyhelminthies as the members of these phyla generally have the potential
to infect humans.
The ITTI team decided that complete vaccines are relevant to the subject and thus fall within the
scope of the project. Although the ITTI team did not know all of the types of vaccines patents a
landscape analysis would discover, the ITTI team subdivided the vaccine category into subunit
vaccines and DNA vaccines.
In reviewing the patents related to vaccines, the ITTI team recognized the need to address the
issue of when the claims of a patent were directed to vaccines mainly used in animals. Given
that a parasitic worms can use an animal as an intermediary (also known as a vector) before
infecting humans and that there is a need to vaccinate livestock against parasitic worms, vaccines
directed solely to the use in animals were included as relevant documents and given a separate
category in veterinary vaccines.104 In some cases, patent documents may have claims directed to
a vaccine useful against all nematodes but the specification of patent would be directed towards a
vaccine useful against parasitic worms that mainly infect livestock.105 In such cases the patent
would be included in the relevant vaccine category and not the veterinary category. In other
cases if the claims were directed specifically to nematodes that infect mainly animals and not
human the patent was sorted into the veterinary vaccine category.106
One of the most important decisions made was how to deal with adjuvants. The main problem
with adjuvants is that an adjuvant patent often claims use in vaccines for parasitic worms in a
large Markush group, along with hundreds of other diseases. On the other hand, an adjuvant
could be limited to just parasitic worms. Faced with these two issues, adjuvants were divided
into two groups, general adjuvants, defined as an adjuvant that listed parasitic worms in a large
Markush group, would be excluded from the report107 and related adjuvants, defined as adjuvants
used just for parasitic worms would be considered relevant.
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Patent Search Methodology
Guess, compute the consequences to see what that guess would imply, and
compare directly with observation to see if it works. If it disagrees with the
experiment, it’s wrong. It’s that simple. It doesn’t matter how beautiful your
guess is, how smart you are, or what your name is. Looking at the universe, the
great power of science, there’s no such thing as authority of nature. If it doesn’t
agree with the experiment, then it’s wrong.
- Richard Feynman

Iterative Process

Figure 17. Iterative development
model. Taken from Wikipedia.

The iterative process is defined as the act of repeating a process with the aim of approaching a
desired goal, target, or result. Each repetition of the process is called an iteration, and the results
of one iteration are used as the starting point for the next iteration. In the field of patent
searching, the iterative process is a searching methodology wherein at the end of a search cycle,
the search is evaluated, and its shortcoming assessed. The shortcomings are then addressed in
the next cycle of searches in order to capture the documents. The next search can be either wider
in scope or could be a narrower search depending on the results gained from the previous search.
In this study, keyword searching identified relevant documents, from which were extracted
further keywords as well as classification codes. The classification codes were used to locate
additional documents. Keywords were adjusted and used for another round of searching.
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Precision and Recall108
The number of patent documents worldwide, including patents (issued, re-issued, and reexamined) and applications, is over 60 million109. Selecting relevant documents from such a
huge dataset can be difficult, and this type of document retrieval is governed by the mathematical
theory of Precision and Recall. Precision is the percentage of retrieved documents that are
relevant and is calculated as the number of retrieved relevant documents divided by the total
number of retrieved documents. Recall is the fraction of relevant documents retrieved and is
calculated as the number of retrieved relevant documents divided by the total number of existing
relevant documents. These concepts are illustrated in Figure 7110 below.

Figure 18. Increasing precision of a search means some relevant results are excluded.

Thus, any set of retrieved of documents will always include a certain fraction of irrelevant
documents, also termed false positives. As a search attempts to capture an ever higher fraction
of relevant documents, the sensitivity of the search will decrease because the proportion of false
positives will increase. In the extreme, every relevant document can only be captured if every
irrelevant document is also captured, as depicted in Figure 8111.
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Figure 19. Inverse relationship between recall and precision.

Stated another way, a high recall means you haven't missed anything but you may have a lot of
useless results to sift through (which would imply low precision). High precision means that
everything returned was a relevant result, but you might not have found all the relevant items
(which would imply low recall).112

Figure 20. An optimal balance can be achieved which is neither 100% precise nor contains 100% recall.

An optimal balance, point C in Figure 9113, must therefore be achieved between precision (degree
of relevance of all retrieved documents) and recall (fraction of relevant documents retrieved). In
terms of patent searching, and in particular searching for relevant vaccine patents within the
parasitic worm vaccine landscape, one deciding on that balance point must have experience in
112
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Wikipedia, the free encyclopedia, http://en.wikipedia.org/wiki/Precision_and_recall.
http://www.ccs.neu.edu/home/jaa/CSG339.06F/Homeworks/hw.01.html.

34

patent searching in general, knowledge concerning the technology involved, and an
understanding of the goal of the search. The purpose of the methodology described in the
previous report and refined in this update is to provide a framework for such a decision-making
process.
A search method example that resulted in high levels of recall and low levels of precision is
semantic searching. In this search method, recall was high but precision was low. The reason
semantic searching may have been less than effective is that the boundaries that create accuracy
in a search, the keywords, were computer generated. Although it is difficult to judge the
precision levels of semantic searching based on our limited attempts, this results seem to indicate
that the keywords generated by a computer do not result in high levels of precision.
Other databases were more successful for obtaining high levels of precision. For example, when
the search string was controlled and the database being searched was efficient, the results that
were obtained were an optimal balance between precision and recall. For example, Derwent is a
pre-screened database, where language and classifications are carefully standardized. Therefore,
precision is increased due to accuracy and efficiency of searching.
Platform Services
U.S. Patent and Trademark Office114
ITTI utilized the USPTO database for classification searching, a patent search platform created
by the United States Patent and Trademark Office, which provides function to search for patents
within any of the USPTO’s classifications. The USPTO database also allows for nonclassification searching.
Thomson Innovation115
ITTI utilized Thomson Innovation, a patent search platform that integrates the best of the suite of
Thomson tools, Aureka, Delphion and MicroPatent. Thomson Innovation is a single,
integrated tool that combines intellectual property, scientific literature, business data and
news with analytic, collaboration, and altering tools in a robust platform.
TotalPatent116
ITTI also utilized TotalPatent, a LexisNexis platform, to search patents and patent
applications world-wide. TotalPatent provides several additional countries that are not
included in other platforms. Also, TotalPatent offers useful tools such as semantic searches,
the ability to search for subsidiary companies and corporate structure, and analytics.
114

http://www.uspto.gov/.
http://info.thomsoninnovation.com/.
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http://www.lexisnexis.com/en-us/products/total-patent.page.
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Deduplication Process and Collapsing into Families
The search results from ITTI’s secondary patent searches were combined to form a single list of
patent documents. The combined search results were placed into Microsoft Excel as publication
numbers and deduplicated. The number of duplicates was taken as an indication of the level of
recall. For example, a high percentage of duplicates would mean that most of the relevant results
had been identified. However, publications numbers with different file extensions, such as PCT
extensions A1, A2, and A3, would be recognized as different even though the numbers
corresponded to the same application.
A further method of deduplication employed Thompson Innovation. A publication number
search was performed and all related INPADOC family members were returned in the result set.
The data was saved as a work file. The same procedure was performed with a different team
member’s search results. One work file could be subtracted from the other, and the size of the
subtracted file would indicate the level of overlap and thus the level of recall being achieved.
The work files could also be merged, and Innovation would automatically remove duplicates in
the merged work file.
Once a compiled list of all search results was deduplicated, the results were then collapsed by
INPADOC family to reduce the initial search results into representative patent family
documents. ITTI gave preference to US documents because these documents were easier for the
team to analyze and they tended to contain the most complete bibliographic information
available. The collapsed list was a much more manageable number of documents which the
team could efficiently code into categories. The team recognizes that the representative family
member could be a divisional application and thus would not claim the full limit of the invention.
Although this could result in an error, either towards inclusion or exclusion, time constraints
prohibited coding of every publication individually.
Results
Relevant/Irrelevant Determination
A master of list of parasitic worm-related documents was assembled following three complete
rounds of searching by each of the three team members.117 On the second round of searching,
about 90% of nearly 2800 documents were repeated among the different members’ results. The
third round of searching generated 4 new INPADOC families and 20 new patent documents.
This increased the percent of repeated documents to nearly 99% Thus, the team was confident
that at least 96% of the helminth-related documents had been captured.
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The keywords used in patent searching are located in Appendix L.
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The results were compiled and a publication number search was performed using Innovation to
expand the families. Approximately 2847 total documents were identified, and these results
were collapsed into almost 447 INPADOC patent families.118 Representative family members
were then subjected to a coding process. Publications that were irrelevant to vaccines directed
towards helminths or were outside the scope of this project were excluded. Documents were also
excluded if there was too little information in the record to support a coding decision, such as
some documents having only a title.
Documents were considered relevant if they specifically claimed a member of either phylum
platyhelminthies or phylum nematoda. Coding was done on the claims of the representative
family members, or, if no claims were available, coding was done using other family members.
INPADOC family members were given preference, but DWPI family members were used
alternatively. Family members were selected in the following order, as available: a U.S.
application (assumed to have the broadest claims), U.S. patent, a PCT application, and finally a
document having claims in English, such as a document from Great Britain or Australia. If no
family members had claims in English, foreign language claims were translated into English
using either a translation provided by Thomson Innovation, Lexis Total Patent, or Google
Translate.119 If there were no family members having claims in their records, the family was
coded using a DWPI summary of the claims, or if absolutely necessary, on the abstract alone. In
the final case, the coding was done very conservatively and the document was excluded unless it
obviously related to a vaccine targeting parasitic worms.
In this manner, over 98% of the results were either assigned to one of the coding categories given
below or were excluded as outside the scope of this report. Many documents were relevant to
multiple categories, but each representative family was placed in only one category, that
category being the best fit for the overall focus of the document. For example, a document
claiming both a complete vaccine and the components to be assembled into that vaccine was
placed into one of the vaccine categories. Alternatively, if the document focused on the process
of making the vaccine, the document was coded to one of the method categories. In general,
there were four major categories for coding documents: vaccines, supporting technologies,
general platforms, and excluded documents. The first two categories were divided into
subcategories. The definitions and criteria for each category are given below. The Master
Coding Document can be found in Appendix A.
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Results are given in approximations because new family members were continually being identified and
publications were added to existing families. Thus, the actual numbers changed each week with total documents
increasing and the number of families decreasing.
119
http://translate.google.com/.
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Coding Categorization of Patent Documents
General platforms.
A document had to specifically claim a type of parasitic worm or parasitic worms in general to
be considered relevant. The technology described in such documents could be useful in
constructing a vaccine directed towards helminths, but could just as easily serve as a platform for
vaccines against a wide range of pathogens. These documents were considered to have a low
level of relevance. While these documents are captured and reported in Appendix A, they are
not included in any of the analysis below.
Vaccines.
Vaccines were divided into two subcategories: subunit vaccines, and DNA vaccines. Subunit
vaccines contain individual helminth antigens or a mixture of a limited number of antigens. The
antigens could either be a portion of a helminth120, a purified surface antigen of a helminth121 or a
chemical a helminth excretes.122 The subunits could be also be expressed by viruses, bacteria, or
other organisms that act as a carrier for a helminth antigen.
DNA vaccines are nucleic acid constructs which, when injected into an animal, cause
expression of an helminth antigen by host cells that take up the nucleic acid constructs These
nucleic acid constructs could be either linear pieces of DNA or RNA, which are short-lived in
the host, or DNA plasmids, which can persist for a period of time.123
To be considered a vaccine-related publication, the representative document must have
claimed compositions of matter having all aspects of a true vaccine: antigen(s), adjuvant (if
necessary), carriers/diluents, and a means or route of delivery. If the claims do not meet these
aspects, or were solely method claims, the family was placed in one of the supporting technology
categories. Merely terming a composition was not sufficient; the claims must have had enough
detail to describe an actual vaccine. Some allowance was made for foreign language documents
in that a broader range of terminology was accepted as a description of a vaccine.
Supporting Technologies.
Some documents claimed parasitic worms in the independent claims yet did not sufficiently
claim a vaccine composition for use in humans. These documents describe the antigenic
components of a vaccine, but lack detail of carriers, adjuvants, and route of administration.
Thus, these documents were coded as one of the supporting technologies which are important for
the construction or manufacture of vaccines. Included in the supporting technologies
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See US4756908A
Id.
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See AU2003294191B2
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See US5021342A; see also, CN100528240C
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subcategories is novel subunit constructs useful in vaccines. As such, these two subcategories
were focused on compositions of matter.
Two other subcategories of the supporting technologies were focused more on methods utilized
in vaccine manufacture. The first such subcategory contains documents describing methods of
making vaccines. The other subcategory contained documents describing methods of producing
subunits useful for vaccines. These method including nucleic acid constructs which could be
used to produce recombinant viruses,124 or cell lines which could be used to produce subunits125
While the former subcategory was mostly for method patent documents, the latter subcategory
contained a mixture of method and composition of matter claims.
A final subcategory under the heading of supporting technologies was for veterinary vaccines.
While the documents in this subcategory described complete vaccines, those vaccines were not
for use in humans, although it is possible some may have been able to be adapted for human use.
These vaccines were targeted towards pigs, horses, dogs, and other domesticated animals. Such
vaccines may be useful not only veterinary purposes but also to prevent transmission of parasitic
worms to humans. Veterinary vaccines were included in the relevant dataset for analysis as the
line between purely veterinary vaccine, veterinary vaccines with human applications, and
vaccines with veterinary applications was generally too close to make an absolute call on
whether to include or exclude veterinary related documents.
The heading of supporting technologies thus contains a broad spectrum of patent documents
covering a variety of different technologies. However, all of these documents are relevant to the
production of helminth vaccines and the prophylactic treatment of human populations. The
entire list of these documents is presented in Appendix A.
Note on the order of placement
As mentioned above, relevant documents may fit in multiple categories, but these documents
were placed in the category which was the most relevant to the overall focus of the document.
The order of placement was:
1. Subunit vaccines
2. DNA vaccines
3. Subunits useful for vaccines
4. Methods of making vaccines
5. Methods of producing subunits
6. Veterinary vaccines

124
125

See CN102277373A
See IN200705429P4
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Documents were placed in the highest category in which the claims from that document fit.
However, if no claims were available in the record of that document or any of its family
members, the document were conservatively coded, mostly in the lower categories. If the
available record mentioned multiple pathogens, the document without claims was often placed in
the platform category.
Excluded irrelevant documents
Approximately half of the documents were excluded as irrelevant or as having insufficient
information to allow coding. The full list of these documents can be found on the Master Coding
Sheet in Appendix A, but it is useful to detail the reasons for exclusions here, to clarify the scope
of the project.
1.
2.
3.
4.
5.

Therapeutic interventions, such as small molecule medicines.
Means of detecting the presence of a parasitic worm.
Diagnostic methods.
Passive immunization.
Antibodies directed against helminths. These could be used in any of the above
categories. A few patent document mentioned using anti-helminth antibodies to stimulate
anti-idiotype responses, but few of those documents disclosed an anti-idiotype
monoclonal antibody that could be used to immunize humans.
6. Adjuvants, when a parasitic worm is not specifically claimed.
7. Use of helminths in autoimmune therapy.
8. Use of helminths for agricultural purposes
9. Delivery systems for vaccines.
10. Immunization schedules, when a particular vaccine formulation is not disclosed.
11. Documents actually related to Plasmodium, a protozoa responsible for malaria. Searches
for the helminths often returned this pathogen as well.
12. Documents which were not related to helminths.

Distribution of coding categories
The relative distribution of the results into the various categories is given in Table I. Almost half
of the search results were considered relevant as either a vaccine document or a document
describing one of the supporting technologies. Analytics was performed on these patent
documents. The remainder of the results are reported in the appendix but were not included in
the analysis.
Table I. Distribution of results (210 families) into coding categories.

Cestode
Vaccines
Subunit vaccines

12.9%
6.7%
6.2%
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DNA vaccines
Supporting Technologies
Novel subunits useful in vaccines
Method of making vaccines
Veterinary vaccines
Nematodes
Vaccines
Subunit vaccines
DNA vaccines
Supporting Technologies
Novel subunits useful in vaccines
Method of making vaccines
Veterinary vaccines
Trematodes
Vaccines
Subunit vaccines
DNA vaccines
Supporting Technologies
Novel subunits useful in vaccines
Method of making vaccines
Method of producing subunits
Veterinary vaccines
Non-Distinguished

0.5%
6.2%
4%
1.5%
0.7%
30.5%
12.9%
12%
.9%
17.6%
5.2%
1.9%
10.5%
49%
23.3%
16.2%
7.1%
26.2
21.4
4%
.5%
.5%
8.1%

Vaccines
Subunit vaccines
DNA vaccines
Supporting Technologies
Novel subunits useful in vaccines
Method of making vaccines
Veterinary vaccines
Platform technologies
Excluded as irrelevant

3.33%
3.33%
0.0%
4.8%
.95%
2.4%
.95%
2.0%
50.1%

Relevant Helminth Vaccine and Vaccine Technology Documents
Searching was done for helminth-related patent documents which were then categorized based
on their relationship to vaccines for parasitic worms. Not all documents were specific as to
whether the technology could be used towards helminths that infect predominately human;
helminths that infect predominately animals; or both. The team decided to err on the side of
inclusion, so that a document was considered relevant if it mentioned a vaccine that targeted
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helminths generally, a helminths that can infect humans. Documents representing each family are
presenting in Table II. Full information on those documents can be found in Appendices B and
C.
Table II. Documents representing the 210 relevant patent families referencing helminth vaccine and related
technologies.

Publication
Number
AU2010241253B2

Title - DWPI

Assignee/Applicant

US8211438B2

Vaccine composition useful for
vaccinating a patient against
hookworm infection, comprises
hookworm antigens Na-APR-1 and
Na-GST

Constructing peptides based on three- FUNDACAO OSWALDO CRUZ
dimensional structure of homologs,
useful as vaccines for protecting
against helminth infections and for
diagnosis

Protective protein derived from
parasite protease, e.g. Fasciola
hepatica may be detected using ex
vivo animal model, useful for, e.g.
vaccinating mammals against
parasite
ES2376874T3
Novel Schistosoma mansoni
recombinant protein of specific
molecular weight, useful as
protecting antigen against
Schistosoma and Fasciola infection
affecting humans and animals
US7303752B2
Composition useful for vaccinating
or eliciting immune response against
hookworm in mammal, comprises
copy of recombinant or synthetic
antigen or their fragments derived
from hookworm, and carrier
US20070079388A1 Composition for producing immune
response, comprises human
hookworm, in carrier, and human
hookworm is produced by
administering non-adapted human
hookworm to non-human primate,
obtaining fecal material, isolating
human hookworm

The George Washington
University,Washington,DC,US

BRPI9808251B1
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FUNDACAO OSWALDO CRUZ

The George Washington
University,Washington,DC,US

The Secretary of State for Defence

US7144878B2

Preventing and treating roundworm
infestations in animals, comprises
orally administering parasiticidal
formulation comprising non-aqueous
liquid, thickening agent and different
agents effective against nematodes to
animals
New parasitic helminth proteins,
pref. from Dirofilaria immitis used to
protect animals from helminth
infection, pref. heartworm

IVX Animal Health Inc.,St.
Joseph,MO,US

New Dirofilaria immitis parasite
protein exhibiting antigenic crossreactivity with human Onchocerca
volvulus filarial parasite protein and
immune-reactivity with sera having
heartworm infection, for diagnosis of
heartworm infection
Composition containing polypeptides
from adult Taenia solium, useful for
detecting taeniasis, particularly
differentiation between infection by
adults and larvae

New England Biolabs Inc.,Beverly,MA

CA2403985C

Inducing angiogenesis in a tissue
using the Ov-ASP protein isolated
from the nematode Onchocera
volvulus is useful to treat circulatory
or vascular disease such as ischemia

DE69737691T2

Vaccine for controlling infection by
helminth parasites containing new
peroxiredoxin or beta-tubulin,
particularly used to combat liver
fluke

NEW YORK BLOOD CENTER
INC.,NEW YORK,NY,US | CASE
WESTERN RESERVE
UNIVERSITY,CLEVELAND,OH,US |
THE UAB RESEARCH
FOUNDATION,BIRMINGHAM,AL,US
Dalton John Pius Blackrock Dublin IE

US6673345B2

Novel isolated protein useful for
identify a compound capable of
inhibiting astacin metalloproteinase
activity of a parasite

CA2153494C

US6790630B1

US6756043B2
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COLORADO STATE UNIVERSITY
RESEARCH FOUNDATION,FORT
COLINS,CO,US | HESKA
CORPORATION,FORT
COLLINS,CO,US

The United States of America as
represented by the Department of Health
and Human Services Centers for Disease
Control and Prevention,Washington,DC

Heska Corporation,Fort Collins,CO

US20050208063A1 Thiol proteases with Cathepsin Ltype activity useful in vaccine
formulations against helminth
parasites

John P. Dalton,Dublin,IE

US6489448B1

Nucleic acid encoding thiol-specific
antioxidant protein of helminth
larvae useful for treatment or
prevention of helminth infection,
specifically heartworm

Heska Corporation,Ft. Collins,CO

US6455039B2

Isolated parasitic helminth
macrophage migratory inhibitory
factor and related nucleic acid, useful
for protecting animals from
heartworm or onchocerciasis.

Heska Corporation,Ft. Collins,CO

US6414115B1

New isolated parasitic nematode
transglutaminase genes used to
develop products for the detection,
prevention and treatment of
infections by parasitic nematodes

Heska Corporation,Fort Collins,CO |
Board of Regents The University of
Texas System,Austin,TX

US6413521B1

A helminth parasite antigen with
The Barbraham Institute,Cambridge,GB
aminopeptidase like activity for use
in vacuums to stimulate an immune
response against helminth parasites
pref. gastric nematodes of the gastrointestinal tracts of mammals
A new parasitic helminth Antigen-2
Heska Corporation,Fort Collins,CO
protein, designated DiAg2, from
Dirofilaria immitis reacts with sera
from immune dogs and is useful to
prevent and treat parasitic helminth
infection, particularly heartworm in
dogs
New ankyrin proteins encoded by
Heska Corporation,Fort Collins,CO
nucleic acids which hybridize to
nucleic acids from Dirofilaria and
Brugia are useful to immunize
against platyhelminth parasites which
cause disease such as heartworm,
elephantitis and hydrocele

US6392017B1

US6365569B1
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US6352836B1

BR199815440A

US5948644A

US5942413A

New isolated thioredoxin peroxidase
type-2 nucleic acid obtained from a
Dirofilaria and Brugia, used to
develop products for protection
against parasite helminth disease
such as heartworm disease
Homogeneous population of parasite
cells for long term in vitro culture
particularly derived from nematodes,
suitable for use in vaccines, also
related antibodies and anti-idiotypic
antibodies for diagnosis of infestation
and treatment
Excretory-secretory antigens from
parasitic nematode(s) confer
immunity to responsive hosts to
parasitic nematode stages

Heska Corporation and Colorado State
University Research Foundation,Fort
Collins,CO

Vaccines comprise antigens derived
from parasitic nematodes useful for
passive immunisation against
roundworm, whipworm, filarial
worm, threadworm and hookworm.

Biotech Australia PTY
Limited,Roseville,AU | Commonwealth
Scientific and Industrial Research
Organization,Campbell,AU

DK703789T3

UNIV MISSISSIPPI

Biotechnology Australia Pty
Ltd.,Roseville,AU | Commonwealth
Scientific & Industrial Research
Org.,Campbell,AU

ANDREWS STUART JOHN |
DALTON JOHN PIUS

US5871738A

Antigens derived from parasitic
nematodes used in vaccines against
hookworm, roundworm, whipworm,
filarialworm, or threadworm

Biotech Australia Pty.
Limited,Roseville,AU | Commonwealth
Scientific and Industrial Research
Organization,Campbell,AU

CA1340301C

Protein derived from parasitic
nematode species used to provide
protective immunity against
nematode parasites of man and
domestic animals

COMMONWEALTH SCIENTIFIC
AND INDUSTRIAL RESEARCH
ORGANIZATION,CAMPBELL,AU |
BIOTECHNOLOGY AUSTRALIA
PTY. LTD.,AU

EP836481A4

HESKA CORP
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US20030091591A1 Use of packaging defective alphavirus expression vectors for prodn. of
protective cpds. for protecting
animals from disease, partic.
toxoplasmosis

HESKA CORPORATION

US5753236A

New epitope contg. fragments of
Schistosoma mansoni 28 kD protein
prepd. by digestion with V8 protease,
useful as vaccine components

Institut Pasteur de Lille,Lille,FR | Institut
Pasteur,Paris Cedex,FR

JP03103592B2

Protein complex parasitic nematode
useful as an immunogen and
anthelmintic agent in vaccine

MUNN E A

DE4419264B4

Sm14 from Schistosoma mansoni
binds fatty acids and confers up to
100 percent helminth infection
protection; useful in vaccinations
against helminth diseases.

Fundação Oswaldo Cruz (Fiocruz) Rio
de Janeiro BR

CA2215529C

Vaccine which protects animal from
Trichinella infection comprises betatyvelose-contg. compsn. or
mimetope, which is beta-tyvelose or
beta-tyvelose joined through
glycosidic linkage to
mono:saccharide to form
oligosaccharide, and excipient
Antigenic polypeptide(s) of Taenia
ovis used in vaccines to protect
ruminants against infection by
cestode parasites and to develop
identifying probes

COLORADO STATE UNIVERSITY
RESEARCH FOUNDATION,FORT
COLINS,CO,US

DK173779B1

New protein contg. epitopes of P28
Schistomonas antigen corresp. DNA
sequences and transformed cells and
viruses, useful in vaccines and
diagnosis

TRANSGENE SA

US5541078A

New immunogenic peptide sequence
from Echinococcus granulosus for in
vitro diagnosis of hydatidosis by
ELISA and radioimmunological
methods, also as vaccine against

Institut Pasteur de Lille,Lille Cedex,FR |
Institut National de la Sante et de la
Recherche Medicale (Inserm),Paris
Cedex,FR | Institut Pasteur,Paris
Cedex,FR

US5618542A
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Coopers Animal Health NZ
Limited,Upper Hutt,NZ | University of
Melbourne,Victoria,AU | Ministry of
Agriculture & Fisheries,Wellington,NZ

hydatidosis

US5492695A

Vaccine for susceptible hosts against
non-adapted parasites e.g. dirofilaria
immitis esp. used to protect cats
against heart-worm

Colorado State University Research
Foundation,Fort Collins,CO,US

US5422263A

DNA encoding sequence
homologous to trichinella spiralis
sequence of 53 kilodalton excretorysecretory antigen used in diagnosis
and as vaccine for trichinellosis

The United States of America as
represented by the Secretary of
Agriculture,Washington,DC,US

JP02759652B2

Membrane associated proteins from
nematodes used in the prodn. of
vaccines against haemonchosis,
ostertagiasis and other nematode
infections

BABURAHAMU INST

US5219566A

New cDNA encoding polypeptide of
Schistosoma mansoni includes
protein epitope(s) present on
Schistosomula surface, used in
vaccines against bilharziasis

The Johns Hopkins
University,Baltimore,MD,US

US5021560A

Glyco:protein cpds. from mollusc
haemo:cyanine and glycan epitope(s)
with same antigenicity as shistosoma
mansoni surface antigen, useful for
making anti-bilharzia vaccines and
protective sera
DNA encoding onchocerca/volvulos
volvulos antigen used to express
recombinant antigen for vaccine
against onchocerciasis or river
blindness

Institut Pasteur,Paris,FR | Institut Pasteur
de Lille,Lille,FR | Institut National de la
Sante et de la Recherche Medicale
(INSERM),Paris,FR

US5021342A

USN7366844N

DNA encoding sequence
homologous to trichinella spiralis
sequence of 53 kilodalton excretorysecretory antigen used in diagnosis
and as vaccine for trichinellosis
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University Hospitals of
Cleveland,Cleveland,OH,US

US4795633A

Vaccine for swine Trichinosis
comprising inert new:born larvae of
Trichinella spiralis emulsified with
an adjuvant

IE59292B1

The United States of America as
represented by the Secretary of
Agriculture,Washington,DC,US

BRITISH TECH GROUP

USN7068499N

Vaccine for swine Trichinosis
comprising inert new:born larvae of
Trichinella spiralis emulsified with
an adjuvant

US4656033A

Vaccine against Schistosoma
mansoni contg. soluble antigen from
larvae or adults, administered with
BCG adjuvant

US4396600B1

Antigenic prepn. obtd. by saline extn.
of schistosome worms useful in
vaccines against schistosome
infections

US4314992A

Fascioliasis vaccine prodn. by
gamma irradiation of
meta:cercaria(e) obtd. by infecting
Lymnaea natalensis snails with
Fasciola gigantica miracidia

BITAKARAMIRE PETER K

US3676547A

Ascaris suum vaccine for pig
immunization obtd from second and
third stage larvae

Eli Lilly and
Company,Indianapolis,IN,US

US3395218A

Anti-nematodal vaccines

ALLEN & HANBURYS LTD
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The United States of America as
represented by the Department of Health
and Human Services,Washington,DC,US

US20130064853A1 New antigens from the fourth stage
larvae of non-blood feeding parasitic
nematodes, useful for raising an
immune response and for treating,
preventing or reducing symptoms of
diseases such as Bovine ostertagiasis
EP2531210A1
New isolated antigen useful in e.g.
vaccine for protecting a mammal
against Strongyloides stercoralis
infection, comprising Strongyloides
stercoralis immunoreactive antigen
protein
US20120128721A1 Large scale production of a full
length Schistosomal paramyosin
coiled coil dimmer composition
comprises contacting a composition
comprising recombinant paramyosin
with a strand separation agent
JP2012519496A
Recombinant Bacillus CalmetteGuerin auxotrophic Pasteur strain
used for controlling human infections
caused by parasites e.g Schistosoma
mansoni, and for controlling tumors,
is supplemented for amino acid
leucine
US20110200640A1 Multivalent anti-helminthic vaccine
comprises recombinant hookworm
antigens and recombinant
schistosome antigens, useful for
vaccinating an individual against
hookworm infection and
schistosomiasis
US20110158998A1 Novel isolated protein comprising
immunogenic, extracellular fragment
of schistosome tegument protein
tetraspanin-1 TSP-1, TSP-2 or 7TM,
useful for preparing
immunotherapeutic composition for
immunizing against schistosomiasis
EP2264057A4
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Smith William David,Penicuik,GB |
Newlands George Fredrick
James,Penicuik,GB | Smith
Stuart,Penicuik,GB | Halliday
Aileen,Penicuik,GB
The United States Of America As
Represented By The Office of
Technology Transfer National Institutes
Of Health,Bethesda, Maryland 208927660,US,101263691 | Thomas Jefferson
University,Philadelphia, PA
19107,US,101093759

THE COUNCIL OF THE
QUEENSLAND INSTITUTE OF
MEDICAL
RESEARCH,Queensland,AU

UNIV GRANADA

EP2485725A2

CN102596226A

Composition, useful e.g. for the
PAH W LLC,New York NY 10017prevention or control of parasitic
5755,US,101347569
infection (Helminthiasis and Fasciola
species) in warm-blooded animal e.g.
sheep, comprises oil adjuvant,
macrocyclic lactone e.g. milbemycin,
and immunogenic polypeptide
Vaccine composition useful for
UNIV TEXAS TECH SYSTEM,US
preventing schistosomiasis comprises
a full length cDNA of the large
subunit of Schistosoma mansoni
calpain cloned into a vector

US20100255037A1 New isolated Haemonchus contortus
polynucleotide and polypeptide,
useful for manufacturing
immunogenic composition for
preventing or treating H. contortus
infection in an animal, and for
identifying analogous proteins from
other helminths
US20030176382A1 New vaccine composition for the
treatment of hookworm infection
comprises aspartyl proteinase from
Necator americanus
US20030129204A1 Protective helminth parasite antigen
used in vaccine directed against
parasitic nematodes of mammalian
gastro-intestinal tract e.g.
Haemonchus contortus

Moredun Scientific Limited,GB

EP992582A3

University of Wales Bangor,Bangor,
Gwynedd LL57 2DG,GB,02522642

AU2003294191B2

New polypeptide produced in a
genetically modified microorganism
containing the amino-acid sequence
of the liver fluke cysteine protease
fused to the sequence of hepatitis B
virus core protein, for use as a
vaccine against liver fluke
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INST PARAZYTOLOGII PAN | INST
BIOTECHNOLOGII
ANTYBIOTYKOW

AU2003295293B2

RU2145876C1

EP2328610A2

CN101563103A

JP2000500474A

New chimeric protein containing
cysteine protease of the liver fluke
fused to hepatitis B core protein or
ubiquitin, useful in treating liver
fluke infection and in inducing
immunicity
Use of anti-helminth vaccines to
control disease associated with loss
of natural immunity esp. for control
of periparturient rise of Haemonchus
in sheep and of type II ostertagiasis

INST OF BIOORG CHEMISTRY |
INST OF PARASITOLOGY POLISH
AC | INST OF BIOTECHNOLOGY
ANTIBIOT

Immunogenic formulation useful for
protecting and/or treating an animal
against a parasitic nematode, and for
vaccinating a susceptible animal
against infection from the parasitic
nematode
Identifying anthelmintic agents
comprises contacting an agent with a
helminth protein having dipeptidyl
peptidase IV activity and resulting in
an increase in blood clotting time

Moredun Research Institute,Bush Loan,
Penicuik EH16 0PZ,GB,101167975

MALLINKRODT VETERINARI INK

MOREDUN RES INST,GB

Isolated nematode antigens useful for
diagnosis, prevention and therapy of
nematode infections prepared by
culturing L4-stage nematode larvae
in vitro in which antigens
immunoreact with protective
antiserum raised against L3 to L4
stage

EP707597A4

MALLINCKRODT VETERINARY
LTD | UNIV MELBOURNE |
PASTORAL AGRIC RES INST NZ
LTD

EP694043A4

MALLINCKRODT VETERINARY
LTD | UNIV MELBOURNE |
PASTORAL AGRIC RES INST NZ
LTD
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EP772679A1

New Schistosoma, partic. S.
haematobium proteins for use as
pharmaceuticals, partic. as vaccines,
blood processing agents and as
anticoagulants

BR199404004A

Isolated polypeptide from Fasciola
DARATECH PTY LTD
species useful as vaccines against e.g.
spread of infection of liver fluke

JP8503935A

Monoclonal antibodies specific for
nematode beta-tubulin and vaccines
contg. a nematode antigen used to
immunise against parasitic infection,
pref. filariasis.

EP554064A1

Vaccine against schistosomiasis
YEDA RESEARCH AND
comprising recombinant Schistosoma DEVELOPMENT CO. LTD.,Rehovot
mansoni integral membrane protein
76100,IL,00268945
or its derivs.

AU638728B2

Vaccine composition for gastrointestinal nematode infections
comprises antigenic component of
e.g. Ostertagia circumcinta extract

DARATECH PTY LTD

EP434909A3

Protein from Haemonchus contortus
and other nematodes used as
therapeutic and prophylactic agent to
protect plants, animals or humans
from parasitic nematode infection

SYNERGEN INC

AU634754B2

Vaccine against liver fluke infection
in ruminants. esp. sheep comprises
glutathione-S-transferase extracted
from adult fasciola hepatica worms

DARATECH PTY LTD

AU198826483A

Monoclonal antibody binds to 68 KD
antigen of schistosoma mansoni to
give immunity

UNIV CLEVELAND HOSPITALS
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IMPERIAL COLLEGE OF SCIENCE
TECHNOLOGY & MEDICINE,London
SW7 2BB,GB,00633556

PT84788B

INST NAT SANTE RECH MED |
PASTEUR INSTITUT

NZ214215A

BIOTECH AUSTRALIA PTY LTD

AU198426739A

Helminth parasitosis e.g bilharziasis
vaccine-medicament is derived from
e.g. ecdysterone, pref. coupled with a
macromolecule esp. protein(s) e.g.
serum albumin

IMMUNOTECH SA

KR2012110430A

New protein useful for diagnosing
and treating liver fluke infection,
comprises specific amino acid
sequences

CHUNG-ANG UNIVERSITY
INDUSTRY-ACADEMY
COOPERATION FOUNDATION

WO2012145355A1

Composition useful for e.g.
producing immune response in
subject and immunizing subject
against Schistosoma infection,
comprises slurry matrix, and antigens

UNIVERSITY OF GEORGIA
RESEARCH FOUNDATION INC.,US |
HARN Donald A.,US | QUEIROZ
Rafaella,US | MCEWEN Lisa,US

WO2012104837A1

Composition useful as antinematodal
composition for treating nematode
e.g. Trichuris muris infection in
subject e.g. human and animal,
comprises non-insect cell or viral
particle expressing exogenous
nematode fusogenic protein
New multivalent vaccine comprising
isolated antigens from filarial
nematodes, useful for preventing or
controlling filariasis in humans and
animals

TECHNION RESEARCH AND
DEVELOPMENT FOUNDATION
LTD.,IL | UNIVERSITY OF VIRGINIA
PATENT FOUNDATION,US |
PODBILEWICZ Benjamin,IL |
AVINOAM Ori,IL | WHITE Judith
M.,US
THE BOARD OF TRUSTEES OF THE
UNIVERSITY OF ILLINOIS,US |
KALYANASUNDARAM
Ramaswamy,US

WO2012067866A3

BRPI1005855A2

FUNDACAO OSWALDO CRUZ |
ALVOS CONSULTORIA
DESENVOLVIMENTO E COM
IZACAO DE PRODUTOS
BIOTECNOLOGICOS S A
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AR76555A1

VERENIGING VOOR CHRISTELIJK
HOGER ONDERWIJS | STICHTING
TECH WETENSCHAPP

FR2898276B1

CENTRE NAT RECH SCIENT | UNIV
CLAUDE BERNARD LYON | ECOLE
NATIONALE VETERINAIRE |
CAMBRIDGE ENTERPRISEA | UNIV
DE LA REPUBLICA | ISNTITUT
AGRONOMIQUE ET VETERI
FUNDACAO DE AMPARO A
PESQUISA

BR200413944A

New isolated nucleic acid molecule
encoding a Schistosoma mansoni
protein, useful for as a vaccine or for
preventing, diagnosing, or treating
Schistosoma mansoni infection

CO5210982A1

NOVARTIS AG | AGRICULTURE
VICTORIA SERV PTY

AU199720786A

Vaccine for schistosomiasis
comprising a non-integrating DNA
sequence encoding Schistosoma
mansoni glutathione S-transferase

UNIV SOUTH ALABAMA

AU199655380A

New vaccines for filarial parasite
infection(s) comprising C-terminal
beta-tubulin amino acid sequence
from a parasite

UPJOHN CO | UNIV MCGILL

AU199535747A

Vaccines against helminth parasites
contain haemo-protein derived from
e.g. flukes such as Fasciola hepatica
for treating cattle

MALLINCKRODT VETERINARY
INC

ZA199408729A

Protective helminth parasite antigen
is used in the stimulation of an
immune response against helminth
parasites in mammals

BIOTECH & BIOLOG SCIEN RES
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FR2656626B1

PASTEUR INSTITUT

WO1990002563A1

Vaccine against Schistosoma
mansoni comprising antigens present
in surface membrane of adult worm

AU198778719A

New recombinant DNA coding for
UNIV AUSTRALIAN
helminth parasite antigen and derived
polypeptide(s), useful for making
vaccines and diagnostic antibodies

DE2936061C2

Vaccine for birds consists of avian
blood contg. immune factors against
viruses, bacteria, protozoa,
nematodes, trematodes and/or fungi

FR2573983B1

MEDICAL RESEARCH COUNCIL |
SIMPSON Andrew John George |
SMITHERS Sidney Ronald

Schmidt Werner Dr.,DE | Wessjohann
Berthold,DE

LEW KENNETH

GB1580539A

Orally administrable antiparasitic
INST NAT SANTE RECH MED
vaccine for immuno-prophylaxis of
trichostrongylosis, strongylosis etc.
opt. administered with adjuvants such
as tetramisole and levamisole

DE1160139A1

Non-living vaccines contng. antigens
stimulating production in the host of
antibodies and which give protection
when injected against diseases
caused by nematod

CH370526A

UNIV GLASGOW
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FR2689906B1

INST NAT SANTE RECH MED |
PASTEUR INSTITUT

FR2688008B1

INST NAT SANTE RECH MED |
PASTEUR INSTITUT

JP02672712B2

JP1457233C

JP05055522B2

Novel EMY162 polypeptide
specifically inducing antibodies
specific to Echinococcus
multilocularis, useful as vaccine
against Echinococcus multilocularis
infectious disease, or as marker for
diagnosing Echinococcus infection
New DNA encoding a 14 kDa
antigen of Ascaris suum infective
larvae, for producing the antigen
protein which is used in a systemic
and mucosa-inductive type vaccine

UNIV HOKKAIDO,JP | HOKKAIDO
PREFECTURE,JP

JP03613577B2

Novel DNA having biological
activity of 16kDa antigen protein of
the pig roundworm, useful as vaccine
for pig roundworm infection

DOKURITSU GYOSEI HOJIN
NOGYO SEIBUTSU SH

CN102558306A

New epitope comprising specified
amino acid sequence, useful for
preventing and/or treating nematode
disease, such as Trichinella disease
or infection

Capital University of Medical
Sciences,CN

JP03692396B2
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DOKURITSU GYOSEI HOJIN
NOGYO SEIBUTSU SH

CN102392031A

New Schistosoma japonicum gene
which is thioredoxin glutathione
reductase gene having specific amino
acid sequence, used in vaccine for
preventing or treating bilharziasis

Shanghai Veterinary Research Institute
CAAS,CN

CN102337265A

New Taenia solium microsomal
RNA (microRNA), useful for
preparing Taenia solium vaccine or
composition for restraining growth
and development of Taenia solium

Institute for Parasitic Disease Chinese
Center for Disease Control and
Preventi,CN

CN102329798A

New Taenia saginata microRNA,
useful for preparing T. saginata
vaccine or composition for inhibiting
growth and development of T.
saginata

Institute for Parasitic Disease Chinese
Center for Disease Control and
Preventi,CN

CN102329385A

New Schistosoma japonicum antiapoptosis protein, useful for
preparing medicine for preventing
and treating Japanese schistosomiasis

Shanghai Veterinary Research Institute
CAAS,CN

CN102277373A

Salmonella expression vector
secreting attenuated Schistosoma
japonicum vaccine useful for
preparing Schistosoma japonicum
vaccine, comprises bacterial
promoter regulating Salmonella
secretion effector protein and
secretion signal
New Echinococcus granulosus
glutathione transferase gene, useful
for preparing a vaccine for cystic
echinococcosis

NANJING UNIVERSITY,CN

New calcium reticulated protein gene
of Echinococcus granulosus, useful
for preparing vaccine for
immunization against Echinococcus
granulosus disease, and for preparing
diagnostic reagent for diagnosing
cystic echinococcosis

Institute for Parasitic Disease Chinese
Center for Disease Control and
Preventi,CN

CN102168100A

CN102168089A
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Institute for Parasitic Disease Chinese
Center for Disease Control and
Preventi,CN

CN102167735A

New recombinant antigen protein of
Schistosoma japonicum SjTollip
useful in preparing vaccine for
preventing and treating Schistosoma
japonicum

Huazhong Normal University,CN |
Institute for Parasitic Disease Chinese
Center for Disease Control and
Preventi,CN

CN102040658B

New Schistosoma japonicum
polypeptide with immunogenicity is
useful for preparing vaccine for
preventing schistosomiasis or drug
for treating schistosomiasis, and for
preparing product for diagnosing the
schistosomiasis
New Schistosoma japonicum protein,
useful for preparing vaccine for
preventing or treating schistosomiasis
and preparing a product for
diagnosing schistosomiasis

Shanghai Veterinary Research Institute
CAAS,CN

CN102070710A

New Clonorchis sinensis specificity
GRA2a antigenic protein, useful for
preparing a medicament for treating,
diagnosing or preventing infection
caused by C. sinensis

Institute for Parasitic Disease Chinese
Center for Disease Control and
Preventi,CN

CN102010863A

New microRNA of Ascaris suum
having difference in sex expression
useful for preparing Ascaris suum
vaccine or Ascaris lumbricoides
vaccine

South China Agricultural University,CN

CN101985468A

New SJ16 recombinant protein,
useful for preparing a bilharziasis
diagnostic reagent, a bilharziasis
vaccine and a medicine for treating
bilharziasis, and as an
immunosuppressive agent
New Schistosoma japonicum zinc
finger protein coding gene useful for
preparing genetically engineered
vaccine for preventing Schistosoma
japonicum infection

SUN YAT-SEN UNIVERSITY,CN

CN102079783A

CN101948836A

CN101935659A

Shanghai Veterinary Research Institute
CAAS,CN

Shanghai Veterinary Research Institute
CAAS,CN

New microRNA isolated from female South China Agricultural University,CN
adult Ascaris suum useful for
preparing ascarid vaccine, preferably
Ascaris suum vaccine or human
ascarid vaccine
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CN101935658A

CN101921787A

CN101921783A

New microRNA specifically
expressed in Ascaris suum male
adult, used for preparing ascarid
vaccine for affecting human ascarid
physiological function or sexual
development and differential function
for preventing ascariasis
New adenosine deaminase gene
isolated from Schistosoma
japonicum, useful for useful for
preparing medicine and schistosomeresisting antibody, screening drugs,
and in serology diagnosis process and
gene therapy
New Schistosoma japonicum L-lactic
dehydrogenase gene useful in
serodiagnosis, screening medicines
and in preparing Schistosoma
antibody

South China Agricultural University,CN

Shanghai Human Gene Team Research
Centre,CN

Shanghai Human Gene Team Research
Centre,CN

CN101921768A

New 14-3-3 protein gene useful for
Shanghai Human Gene Team Research
preparing medicine and schistosome- Centre,CN
resisting antibody, screening drugs,
and in serology diagnosis process and
gene therapy

CN101921767A

New Schistosoma japonicum MF3
gene useful for preparing
schistosome vaccine and
schistosome-resisting antibody,
screening drugs, and in serology
diagnosis process and gene therapy
process
New Schistosoma japonicum
proteasome alpha 5 subunit (SjPSM
A5) recombinant antigen, useful for
preparing preventative vaccines for
schistosomiasis japonica

Shanghai Human Gene Team Research
Centre,CN

New Schistosoma japonicum enolase
gene, useful for gene therapy, and for
preparing Schistosoma vaccine,
selecting medicines, preparing
Schistosoma antibody, and
serological diagnosis

Shanghai Human Gene Team Research
Centre,Shanghai 201203,CN

CN101838639A

CN101748139A
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Shanghai Veterinary Research Institute
CAAS,CN

CN101748138A

CN101748128A

CN101748127A

CN101747422A

CN101690806A

New Schistosoma japonicum
superoxide dismutase gene, useful for
gene therapy, and for preparing
Schistosoma vaccine, for selecting
medicines, for preparing Schistosoma
antibody, and for serological
diagnosis
New Schistosoma japonicum titin
gene, useful for gene therapy and for
preparing schistosome vaccine,
selecting drugs, preparing antischistosome antibody, and
serodiagnosis
New Schistosoma japonicum actin
gene, useful for gene therapy and for
preparing schistosome vaccine,
selecting drugs, preparing antischistosome antibody, and
serodiagnosis
New fatty acid binding protein of
Schistosoma japonicum, useful for
preparing schistosoma vaccine and
anti-schistosoma antibody, for
selecting a medicament, and in
serodiagnosis and gene therapy
New dendrimer-DNA vaccine, useful
for preventing infection caused by
Schistosomiasis japonica

Shanghai Human Gene Team Research
Centre,Shanghai 201203,CN

Shanghai Human Gene Team Research
Centre,Shanghai 201203,CN

Shanghai Human Gene Team Research
Centre,Shanghai 201203,CN

Shanghai Human Gene Team Research
Centre,Shanghai 201203,CN

Southeast University,Wuxi, Jiangsu
214064,CN | Jiangsu Institute for
Bilharziasis Prevention and Control

CN101671690B

New recombinant expression carrier
Shanghai Veterinary Research Institute
comprises Schistosoma japonicum
CAAS,CN
gene, useful for preparing vaccine for
preventing or treating schistosomiasis
and for diagnosing schistosomiasis

CN101671689A

New recombinant expression carrier
with Schistosoma japonicum gene,
useful for preparing vaccine for
preventing or treating
schistosomiasis, and for preparing
product for diagnosing
schistosomiasis
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Shanghai Veterinary Research Institute
CAAS,Shanghai 200241,CN

CN101624422B

New recombinant poly-epitope
antigen of Japanese schistosome,
useful for preparing
immunoprophylaxis vaccine of
schistosomiasis japonica

Shanghai Veterinary Research Institute
CAAS,CN

CN101555483B

New polynucleotide encoding
Echinococcus granulosus fatty acid
binding protein (EgFABP)-Eg95
polypeptide, useful for treating
echinococcosis

SUN YAT-SEN UNIVERSITY,CN |
Institute for Parasitic Disease Chinese
Center for Disease Control and
Preventi,CN

CN101524547A

DNA vaccine useful for preventing
and/or treating Cysticercus cellulosae
infection, comprises eukaryotic
expression vector and Cysticercus
cellulosae antigen, e.g. Cysticercus
cellulosae annexin gene
Eastern schistosomiasis tyrosine
kinase conserved gene useful in
preparing recombinant protein
vaccine and DNA vaccine for
preventing and controlling
schistosomiasis
New echinococcosis egG1Y162
antigen gene obtained from
Echinococcus granulosus, useful for
preparing vaccine or diagnostic
reagent for preventing and treating
human or livestock echinococcosis
New Japanese blood fluke gene
recombinant live vaccine comprises a
protective antigen gene of Japanese
blood fluke and porcine pseudorabies
virus, useful for inducing immune
protection against Japanese blood
fluke
Producing Schistosoma japonicum
integral membrane tetraspanin 2
(TSP2) fusion protein useful in
preparing vaccine for
schistosomiasis, by cloning and
expressing Schistosoma japonicum
TSP2 gene in Escherichia coli

PLA Second Military Medical
University,Shanghai 200433,CN

CN101434962B

CN101475938A

CN101444622A

CN101397558A
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Institute for Parasitic Disease Chinese
Center for Disease Control and
Preventi,CN

Xinjiang Medical Univ.,Urumqi,
Xinjiang 830054,CN

Military Veterinary Institute of Academy
of Military Medical Sciences of Chinese
People's Liberation Army,Changchun,
Jilin 130062,CN

Chinese Academy of Agricultural
Sciences Shanghai Institute of
Veterinary,Shanghai 200232,CN

CN101270361B

New extracellular cycle 2 gene
encoding thrombospondins (TSPs)
protein, useful for preparing a
vaccine against Schistosoma
japonicum

SICHUAN UNIVERSITY,CN

CN101050235A

New Japanese schistosomiasis
natural molecular vaccine candidate
antigen comprises immature insect
egg soluble antigen 66-68kDa
molecule of Japanese blood fluke,
used for reducing propagation of
blood fluke egg
Peptide-DNA bi-vaccine for antiinflection of schistosoma japonicum
based on T-cell epitope

WANG Shi-ping,Changsha, Hunan
410078,CN

CN1986797A

Schistosoma japonicum tegument
antigen gene, its encoding protein
and its application

Parasite Prevention Control Office China
Disease Prevention Control Center |
Shanghai Human Gene Group Research
Center,Shanghai 201203,CN

CN100394984C

Bivalent DNA vaccine for Japanese
blood fluke and preparation process
thereof

Huazhong University of Science and
Technology

CN100497627C

Cloning of Japanese blood fluke
vaccine antigen gene and its
expression and application

TIONAL INST PARASITIC DISEASES
CHINESE CENT D | SHANGHAI
HUMAN GENOME RES CENT

CN1904053B

Fusion gene of Japan schistosome
antigen gene and constituted DNA
vaccin and preparing process

Huazhong University of Science &
Technology,CN

CN100528240C

Preparation method and medicinal
uses of Trichinella eelworm vaccine

ZHANG X

CN100553683C
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UNIV NANJING MEDICAL

CN100398155C

DNA vaccine for preventing
Haemonchus contortus disease of
ruminant

Nanjing Agricultural University

CN100393357C

Young schistosomiasis cell style
vaccine for preventing from
schistosomiasis disease

UNIV CENT SOUTH,CN

CN100335636C

Thioredoxin gene of Schistosoma
japonicum (Chinese Mainland
Strain), useful in preparation of DNA
vaccine for preventing and treating
Schistosomiasis japonica

China Disease Prevent and Cure Control
Center Verminosis Prevent and Cure
Control Office

CN1749395A

Cloning and expression of Japanese
blood flukes SJCXSWL gene and
DNA vaccine

LU ZHIYUE

CN1749394A

Cloning and expression of HGPRT
gene of Japanese blood fluke for
preparation of DNA vaccine

WANG SHIPING

CN100374559C

New protease subunit C3 of
Clonorchis sinensis, and genes
encoding it, for use in a diagnosis
reagent kit, and for use in a vaccine

UNIV ZHONGSHAN,CN

CN100360665C

New type I aldehyde dehydrogenase
of clonorchis sinensis, for use in a
diagnosis reagent kit and for use in a
vaccine

UNIV SUN YET-SEN,CN

CN1670206A

New protease subunit C7-I of
Clonorchis sinensis for use in a
diagnosis reagent kit, vaccine and
pharmaceutical composition

UNIV SUN YAT SEN
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CN1670202A

New microsome glutathione Stransferase-1 of Clonorchis sinensis
for use in a diagnosis reagent kit,
vaccine and pharmaceutical
composition

UNIV SUN YAT SEN

CN1670201A

New fumaric reductase Ip subunit of
liver fluke and polynucleotide
encoding it, for use in a diagnosis
reagent kit, and for use in a vaccine

UNIV SUN YAT SEN

CN1670200A

New lactate dehydrogenase of
clonorchis sinensis for use in a
diagnosis reagent kit, vaccine and
pharmaceutical composition

UNIV SUN YAT SEN

CN1670198A

New thermostable type cytoplasm
malic dehydrogenase of clonorchis
sinensis for use in a diagnosis kit,
and vaccine

UNIV SUN YAT SEN

CN1670197A

New arginase of Japanese blood
fluke, for use in a diagnosis reagent,
vaccine and in a pharmaceutical
composition

UNIV SUN YAT SEN

CN100389831C

Gene engineering vaccine used for
preventing pig cysticercosis and its
preparation method

China PLA Logistic PLA Nanjing
Military Medicine Institute

CN1272435C

Gene of Chinese Mainland SJPP
gene stock of japanese blood fluke,
clone, expression and application

Of Animal XUE Experiment | Shanghai
Animal Biological Technology Research
Centre | China Academy of Science
Shanghai Livestock Verminosis
Research Institute

CN1511588A

Japanese nucleic acid vaccine for
blood fluke, comprises a eukaryotic
expression vector and blood fluke
antigen genes

TONGJI MEDICAL COLLEGE
CENTRAL
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CN1249232C

Schistosomiasis japonica (Chinese
Continental strain) MFS4 gene clone,
expression amd DNA vacine

Shanghai Animal Biological Technology
Research Centre,CN | Of Animal XUE
Experiment,CN | China Academy of
Science Shanghai Livestock Verminosis
Research Institute,CN

CN1100788C

Peptide for vaccine of
schistosomiasis

UNIV BEIJING,CN

CN1100787C

Peptide for vaccine of
schistosomiasis

UNIV BEIJING,CN

CN1100881C

Nucleic acid vaccine for cysticercosis Second Military Medical University of
co-contracted by human and pig
PLA

CN1052011C

Beijing Medical University,CN

CN1061991C

Schistosome vaccine peptide No.3

UNIV BEIJING MEDICAL,CN

CN1068334C

Schistosome vaccine peptide No.2

UNIV BEIJING MEDICAL,CN

CN1061990C

Schistosome vaccine peptide No.1

UNIV BEIJING MEDICAL,CN
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CN1020797C

Beijing Solar Energy Institute

IN201110079P1

Vaccine composition useful for
preventing schistosomiasis comprises
a full length cDNA of the large
subunit of Schistosoma mansoni
calpain cloned into a vector

ZA201102008A

Immunogenic formulation useful for
protecting and/or treating an animal
against a parasitic nematode, and for
vaccinating a susceptible animal
against infection from the parasitic
nematode
New compositions comprising
recombinant or synthetic antigens
derived from hookworm, useful as a
vaccine against hookworm infection,
or for reducing hookworm size or
reducing hookworm burden in a
patient infected with hookworm
Peptide immunogens of lymphatic
filarial abundant larval transcript and
lymphatic filarial vaccine
composition comprising same

IN248555B

IN201101367I4

IN201101366I4

Dominant T epitope of filarial
transglutaminase and chimeric
peptide vaccines for lymphatic
filariasis

IN241402B

Constructing peptides based on threedimensional structure of homologs,
useful as vaccines for protecting
against helminth infections and for
diagnosis

IN200806261P4

New membrane protein Sm29, useful
as vaccines for generating a
protective immunity against
infections caused by helminths,
including Schistosoma and Fasciola,
and for treating allergic diseases
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IN200705429P4

Constructing peptides based on threedimensional structure of homologs,
useful as vaccines for protecting
against helminth infections and for
diagnosis

IN200402472P4

Constructing peptides based on threedimensional structure of homologs,
useful as vaccines for protecting
against helminth infections and for
diagnosis

IN200401050P1

New compositions comprising
recombinant or synthetic antigens
derived from hookworm, useful as a
vaccine against hookworm infection,
or for reducing hookworm size or
reducing hookworm burden in a
patient infected with hookworm

UY28972A1

AU2002335061A8

IN200101455P4

RU2205875C2

CARMONA CARLOS

New compositions comprising
recombinant or synthetic antigens
derived from hookworm, useful as a
vaccine against hookworm infection,
or for reducing hookworm size or
reducing hookworm burden in a
patient infected with hookworm
Novel isolated cyst wall cysteine
proteinase derived from Taenia
solium useful as vaccine for treating
cysticercosis or neurocysticercosis
New Echinococcus granulosus
poly:peptide antigen used to prepare
vaccines for preventing infection by
Echinococcus or Taeniid parasites
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UT LTD | UNIV OF MEL BURN | N JU
ZILAND PASTEHREHL EHGRIKA

AU2002334119A1

AU731026B2

New vaccines comprising a 64p
protein, useful against infectious
diseases borne by blood-sucking
ectoparasites, e.g. malaria, dengue
fever, yellow fever, arboviral
encephalitides, lymphatic filariasis,
plague or Lyme disease
Thiol proteases with Cathepsin Ltype activity useful in vaccine
formulations against helminth
parasites

JOHN P DALTON

AU200020764A

Novel vaccine comprising helminth
larvae and antihelmintic for
providing non-pathogenic productive
immunity against parasites in
ruminants

MX199810276A

Vaccine for controlling infection by
helminth parasites containing new
peroxiredoxin or beta-tubulin,
particularly used to combat liver
fluke

MX190278B

Use of anti-helminth vaccines to
control disease associated with loss
of natural immunity esp. for control
of periparturient rise of Haemonchus
in sheep and of type II ostertagiasis

NZ264575A

Providing non-pathogenic immunity
against parasites in ruminants by
admin. of vaccine contg. helminth
larvae followed by admin. of
anthelmintic after 5-21 days

NEW ZEALAND MEAT RESEARCH
& DE

RU2095082C1

Safe, effective anthelmintic vaccine
contains conjugate of immunostimulating carrier and protective
protein antigen

ATAULLAKHANOV RAVSHAN I |
NEKRASOV ARKADIJ V |
PUCHKOVA NATALYA G | PETROV
REM V | KHAITOV RAKHIM M

ZA199402410A

Taenia ovis antigenic polypeptide
used to develop vaccines to protect
against infection by a cestode
parasite, partic. in ruminants.

PITMAN MOORE NEW ZEALAND
LIMIT | PASTORAL AGRIC RES INST
NZ LTD | UNIV MELBOURNE

68

NEW ZEALAND MEAT RESEARCH
& DE

EG19342A

NZ245236A

NAT RESEARCH CENTER

Protein complex parasitic nematode
useful as an immunogen and
anthelmintic agent in vaccine

CS274305B1

LUKES STEPAN

CS274304B1

LUKES STEPAN

CS273807B1
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Vaccine against Schistosomiasis
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parasites

NL255469B

Non-living vaccines contng. antigens
stimulating production in the host of
antibodies and which give protection
when injected against diseases
caused by nematod
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Analysis
Categories of Analysis
Analysis is presented for the overall dataset (210 relevant families) as well as the four major
relevant categories, Cestodes, Nematodes, Trematodes and nonspecific helminths. The
subcategories under each of these major headings were pooled together and analyzed as a group
in order to present a large enough dataset for generating meaningful results. In most instances the
data within the four groups was pooled together and analyzed as a group in order to present a
large enough dataset for generating meaningful results. Platform technologies were not analyzed.
ThemeScape Map of Derwent Data
A graphical representation of the results was generated using ThemeScape, a tool within the
Aureka platform initially developed by Aurigin Systems, Inc., and now available through
Innovation.126 ThemeScape creates a virtual “map” of patent data by extracting keywords from
the documents and plotting those topics in relation to one another. “Islands” are formed by
closely related topics and “mountains” are formed when a large number of documents all contain
the same or similar keywords. Gaps between distantly related topics represent an “ocean.”
ThemeScape is a powerful tool which can reveal relationships within a large dataset that are not
otherwise apparent.
ThemeScape provides options for the sources of keywords within each document. The maps
presented below were derived from the DWPI title, DWPI abstract, and claims in English from
one representative of each INPADOC family. Extracting data only from representative
documents prevents large patent families from skewing the results and gives equal weight to
each invention. Not all references had this DWPI data in their records, so the maps represent a
subset of the entire datasets.
The map in Figure 20 shows the topic found within the overall dataset of relevant documents.
Many of the topics agree with the coding criteria. At the center left of the map is a series of
mountains labeled with “Taenia Ovis, Serine Protease and Proenzyme” which represents the
subunit vaccines category for the subgroup “Cestode”. This isolated grouping concurs with the
patent documents analyzed as taenia document tended to refer only to taenia and not other types
of helminths.127

126
127

http://www.intellogist.com/wiki/Report:Thomson_Innovation/Viewing_Results/Analyzing_Results/ThemeScape.
See US5618542A
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At the center top and extending to the top right of the map contains a series of islands containing
mountains labeled “Helminth, Ostergitae, Heartworm Onchocerciasis and Proteins Multivalent
Proteins. This chain of mountains represents two unique categories, the first being the coding
category of veterinary vaccines under the category of nematodes. Additionally this chain of
mountains also represents subunit vaccines in regard to both veterinary vaccine for nematodes
and also for vaccines to nematodes in general.
The largest chain of islands extending from the center of the map to the bottom right represents
both nematode vaccines as well as trematode vaccines as the labels “Nematode, Fasciola,
Hookworm and Schistosoma” are present. This chain of islands is related to both DNA vaccine
technology and subunit vaccine technology. These different types of technology also related to
both trematodes and nematodes.

Figure 21. ThemeScape map of the representative documents from 752 helminth vaccine and related technology
documents. These documents collapsed to 207 family members out of the 210 documents. The dots on the map are
assignees according to the legend below.
Color
Assignee
Moredun
Pasteur
Mallinckrodt and
Merck
Fundacao
Oswaldo Cruz
Colorado state
Heska
U Melbourne
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The Themescape map also indicates the involvement of different assignee in the various fields of
technology. The distribution and clustering of the assignees into distinct islands and distinct
mountains suggests that these top seven assignees are generally working in separate
technological fields.
In summary, the Themescape map illustrates the coding of the documents successfully placed the
majority of the documents into correct subcategories as the labels on the peaks also correspond
to the subcategories. These maps not only reveal the relationships between the different
technologies in each group but they also validate the document coding protocol which is the
basis for the further analytics presented below. Additionally, the map suggests that each of the
top seven assignees provided are involved in distinct areas of helminth vaccine and vaccine
related technology.

Priority Country v. Document Count
Important questions to ask in the analysis of patent data is “where does the technology come
from?” and “where is the technology being used?” The first question can be answered by
analyzing the priority country, which is the country in which the priority patent document is
filed. Further data can be gleaned from the country in which the top assignees are based, which
is presented below. The second question can be answered by analyzing the multi-jurisdictional
filings, which also follows below.
Although information regarding the priority country is useful, it does not necessarily indicate the
source of the technology. For example, publications HK1154041A0 and HK1156969A0 are
assigned to Medicago, Inc., a Canadian company. However, Medicago128 tends to file
applications first in the U.S., and the priority documents for both of these references are U.S.
applications. Also, IN200503876P1 is assigned to a group of French entities - CNRS, the
Pasteur Institute, and the University of Paris - but the priority document is a Canadian
application. Thus, some assignees file first in other jurisdictions, perhaps to take advantage of
that country’s patent laws or because the patent will be practiced primarily in that country. For
example, Medicago has a manufacturing plant in the U.S., although its research facility is
apparently in Canada.
Most documents have priority data recoded in the Innovation database, but a few do not. In the
majority of cases, priority data can be found through patent family members. When possible,
priority information was added to the data. Highlighted cells in the files presented in Appendices
C and D indicate such manually corrected data.

128

http://www.medicago.com/.
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The priority country information for vaccine patent documents is presented in Figures 12 and 13.
China is by far the largest source of priority documents. The United States and Great Britain are
secondary sources, followed by Russia, Brazil, Australia and New Zealand.
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Figure 22. The country from which
an innovation represented by a
relevant family member likely
originated from. The determination
was based on several criteria.
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Figure 23. Counties from which an invention related to helminth vaccine technology originated. Countries shown
in white have are not the origin of any Helminth vaccine technology amongst the 210 families. Multijurisdictional
agencies, such as WIPO and the EPO, are not indicated.

Top Vaccine Families for Multi-Jurisdictional Filings
Vaccine technologies that have been transferred to the most other countries were calculated by
first determining the size of each INPADOC family within the vaccine document dataset. This
data may be slightly skewed because applications filed in certain jurisdictions are not recorded as
being members of INPADOC families.129 These jurisdictions include Hong Kong, India,
Mexico, the Philippines, Portugal, Taiwan, and Viet Nam. For this reason, the TotalPatent
Extended Family was also retrieved for each of the largest INPADOC families to try to capture
family members from these jurisdictions. It is still possible these jurisdictions remain underrepresented in the dataset. The extended family was not retrieved for all documents because the
export functions of TotalPatent do not allow this data to be captured in a convenient manner.
The number of jurisdictional filings was determined by combining the INPADOC, DWPI, and
TotalPatent families for each representative document.
Twelve representative family members had INPADOC families with 10 or more members. The
top family was represented by RU2145876C1, an older document whose family already contains
16 members. The INPADOC family represented by RU2145876C1 has also been filed in 32
different jurisdictions, which is the most of this group. Two families are assigned to Merck and
two to Biotech Australia . No other assignee is represented multiple times. The top ten families

129

See also Notes on Patent Families in Appendix M.
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according to filings in different jurisdictions are shown in Table III, and the details of each
family can be found in Appendix E.	
  
Table III. Top Multi-Jurisdictional Filings per INPADOC Family.
Publication
Assignee/Applicant Filing Jurisdictions
Number

US5942413A

AT, AU, CA, DE, DK, EP, ES, GR, JP,
NZ, US, WO

US200502080
63A1

Biotech Australia
PTY
Limited,Roseville,A
U | Commonwealth
Scientific and
Industrial Research
Organization,Campb
ell,AU
Biotech Australia
Pty.
Limited,Roseville,A
U | Commonwealth
Scientific and
Industrial Research
Organization,Campb
ell,AU
John P.
Dalton,Dublin,IE

DE69737691T
2

Dalton John Pius
Blackrock Dublin IE

US5871738A

JP03103592B2 MUNN E A

Tota
l
num
ber
of
juris
dicti
ons
12

AT, AU, CA, DE, DK, EP, ES, GR, JP,
NZ, US, WO,

12

AT, AU, CA, DE, DK, EP, ES, GB, JP,
NZ, PT, US

12

AT, AU, BR, CA, CN, DE, EP, ES, GB,
MX, NZ, US, WO

13

AT, AU, CA, DE, DK, EP, ES, GB, HK,
IN, JP, NZ, US, WO, ZA

15

75

BRPI9808251
B1

AT, AU, BR, CA, DE, EP, JP, NZ, TR,
US, WO

11

RU2205875C2 UT LTD | N JU
ZILAND
PASTEHREHL
EHGRIKA | UNIV
OF MEL BURN

AT,AU,BG,CA,CZ,DE,EP,ES,GB,HU,JP,
MX,NO,NZ,WO,ZA

16

DK173779B1

TRANSGENE SA

AT, AU, CA, CN, DE, DK, ES, EP, FR,
JP, PH, US,

12

DK703789T3

DALTON JOHN
PIUS | ANDREWS
STUART JOHN

AT, AU, DE, DK, EP, ES, GB, GR, HU,
JP, NZ, SI, US, WO ,ZA

15

AU, BR, DE, EP, ES, JP, MX, NO, NZ,
RU, US, WO, ZA

13

MX190278B

Global Filing Trends for Helminth Vaccines
The previous section assessed filing trends for individual family trends. The relevant dataset was
analyzed to determine the jurisdictions in which the entire vaccine population was filed. The
INPADOC and DWPI patent families were combined for each reference document, and each
jurisdiction was counted only once per family. For example, if a representative document had
three European Patent Office applications, the EPO was counted once for that family. The
TotalPatent families were not incorporated into this dataset, due to the difficulties with exporting
such data. Thus, certain jurisdictions such as India, Taiwan and the Philippines may be underrepresented.
Of over 230 possible different jurisdictions in which patent applications could potentially be
filed, helminth vaccine families were filed in a total of 45 jurisdictions. As shown in Figure 14,
North America and Europe are popular locations for assignees to seek protection for inventions
directed towards parasitic worms. Of Asian countries, China, India, Japan, and Hong Kong were
targets for filing. Australia and New Zealand also were targeted jurisdictions for filing.
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However, Central and South America, other than Brazil, were poorly represented, and no filings
were done in any African country other than South Africa. Countries are only shown in Figure
14 if at least one filing occurred in that country.
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Figure 24. Distribution of
jurisdictional filings of the 210
vaccine patent families. This data is
also plotted in Figure 25.
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Figure 25. Global filing trends by country. The number of patent families that have sought protection in a given
country are indicated by colors. Countries shown in white have no identified filings among the 210 family
members. Multijurisdictional agencies, such as WIPO and the EPO, are not indicated.

The jurisdictions where each patent family chose to seek patent protect was also plotted on a
world map (see Fig. 15, above). Each jurisdiction is indicated once per family. For example, if a
given patent family filed three U.S. applications, the United States was counted once for that
family. Greenland was considered part of Denmark for this analysis. Also, the former
Yugoslavia was indicated under Serbia and Montenegro, the former Czechoslovakia under the
Czech Republic, and the former Soviet Union under Russia. Multijurisdictional agencies were
not plotted. Nearly 70% of patent families had filed PCT applications with WIPO, so excluding
PCT filings probably did not skew the results, as each country was affected equally. Also, since
the map only indicates countries where PCT applications entered the national phase, the map
gives a more accurate portrayal of the jurisdictions in which assignees are most interested.
However, exclusion of filings at the European Patent Office (EPO), probably does leave some
European countries slightly underrepresented on the map. Other multijurisdictional agencies not
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indicated on the map are the Eurasian Patent Office (EAPO)130 which consists of countries
belonging to the former Soviet Union and in which 20 patent families filed, the African Regional
Intellectual Property Organization (ARIPO)131 which currently represents 18 nations and in
which seven patent families filed, and the Cooperation Council for the Arab States of the Gulf
(GCC)132 which represents six nations on the Arabian peninsula and in which two patent families
filed.
The map demonstrates that the majority of patent families file in just a few countries. The top
nations for filings, indicated in red, are Australia, Canada, China, Japan, the Republic of Korea
(South Korea), and the United States. Secondary target nations, indicated in purple, are Brazil,
Germany, India, Mexico, and New Zealand, followed by a group (in blue) that includes Austria,
Norway, Russia, Spain, and South Africa. A final group (in green) includes the Philippines,
Vietnam, and several European nations. No other nation had more than 20 patent family filings.
Filings were particularly sparse in South America and Africa.
Top Assignees by Patent Document Count
Assignee data for patent documents is often inaccurate. The patent rights could be sold to
another assignee, who does not record the assignee. Also, a company holding the rights changes
its name or is sold in toto and new assignments are not recorded. Some companies do not record
an assignment until a patent is allowed, so published applications that are later abandoned or
rejected do not have assignment data. Outside of the U.S., university faculty members retain
rights in their inventions so the name of the university is not given on the patent document.
None of the patent databases maintain accurate updates for such changes or account for such
missing data.
Correction of patent assignee information must be performed manually. While this represents a
burden on clinic members’ time, such information would is invaluable to the use of the clinic
report. Accurate assignee information is essential in order for the report data to be updated, and
so the correct owners of the technologies can be contacted for licensing inquiries.
The main protocol for correcting assignee names is to use Google, searching for the company
website or new releases about the company. Business Week133 is a great source of information,
as are technology-specific business reporters such as Fierce Biotech134. These sources reveal the
current accurate name of the company listed as the assignee or whether the company is now a
wholly-owned subsidiary of a larger company.
130

http://www.eapo.org/en/.
http://www.aripo.org/.
132
http://www.gcc-sg.org/eng/.
133
http://www.businessweek.com/.
134
http://www.fiercebiotech.com/.
131
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If no information was readily obtainable, the assignee was searched using Innovation, restricting
the date field to after the publishing date of the known document. The Derwent Assignee field
may have another assignee commonly listed with the company being researched. A Google
search of the two names together sometimes revealed a link between the two, such as a name
change or an acquisition. The Derwent assignee code135 is another source of assignee
information. Other companies may be linked to the same code, such as ASTR being used for
both AstraZeneca and its acquired company MedImmune.
If the only information available is the inventor name(s), then the document was located on
Google Patent136. This website has hyperlinks to other patent documents by the same inventor
which may have assignee data recorded. The name of the inventor was also searched on Google
to find an association between the inventor and a particular company. To make the search more
accurate, the search includes both the inventor’s name and some keywords from the patent
document. LinkedIn137 and other networking websites are another source of information, and
can be especially useful if an inventor is associated with multiple companies. Typically the date
of the application can be associated with a date range for when the inventor was working for one
company rather than another. Since patent applications can be filed months if not years after the
date of the invention, this latter method was used with caution.
Using the above methodology, the assignee information for each relevant document in the
vaccine and supporting technologies categories was manually corrected as accurately as possible.
The results were then sorted on assignee names to reveal the number of patent families
associated with each assignee. The two categories were analyzed together so a single list of
assignees was generated, which is presented in Table IV.
Table IV. Assignees with the Most INPADOC Patent (210 Families).
Standardized	
  Assignee	
  
Heska	
  
Merck	
  &	
  Co.	
  	
  
Institut	
  Pasteur	
  
AusBiotech	
  
Biotechnology	
  and	
  Biological	
  Sciences	
  
Research	
  Council	
  

Number	
  of	
  families	
  
12	
  
9	
  
7	
  
5	
  

Home	
  Country	
  
U.S.A.	
  
U.S.A.	
  
France	
  
Australia	
  

5	
   U.K.	
  

	
  
135

http://ip-science.thomsonreuters.com/support/patents/dwpiref/reftools/companycodes/lookup/.
www.google.com/patents.
137
http://www.linkedin.com.
136
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Publication Year v. Patent Document Count
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Trends in publication of patent documents were analyzed for the entire dataset as well as for the
three major categories, Cestodes Nematodes, and Trematodes. Non-distinguished patent
documents were not charted due to the extremely low number of documents. Publication date
was chosen as the parameter for analysis, which indicates publication of applications generally
18 months after filing and publication of patents after allowance. In the few cases in which the
publication date was not recorded, the year of publication could usually be found in DWPI data
such as the DWPI update information. Additionally, the earliest published family member of an
INPADOC family was used in this analysis as it would correlate with filing date of each families
priority document.

Figure 26. Publication trends for patent families for the entire data set. The year of publication of each
representative document of the 210 families is shown.

The earliest representative family member was a U.S. patent issued in 1972, as shown in Figure
16. The second place document was published 8 years later in 1980. From the early 1970’s until
1980s it appears only two patents. After 1980, the rate of patent publications directed towards
helminth vaccines increased from 1 ever 8 years to 1 to 2 documents ever year. In the early
1990’s the average number of publications leapt to roughly 5 publications a year, possibly
because the TRIPS Agreement took effect in 1996 and patent applications began to be published
18 months after filing. The average number of filings per year remained around 5 until 2000 and
onwards where the rate of publications began to steadily climb, up to 24 in 2012. The number of
publications in 2013 was approximately equal to 3. Considering this report includes a thorough
search of patents only up to early March 2013, the search did not cover the entire 2013 calendar
year.
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Figure 27. Publication trends for patent families grouped into the category of Nematodes

The earliest representative family member was a foreign patent issued in 1980. The second place
document was published seven years later in 1987. Patent publication spiked in the late 1990’searly 2000’s and again starting around 2010. Seven patent family representatives were published
in both 2011 and 2012. There has been nothing published for 2013.

Figure 28. Publication trends for patent families grouped into the category of Cestodes

The earliest representative family members were three patents issued in 1991. The second place
documents were published four years later in 1995. There were no patent documents from 19992002. From 2003 to 2009 there was a steady trickle of patents published. Publications spiked in
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2011 and 2012, with four cestode patent publications issued both years. There has been nothing
published for 2013, yet.
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Figure 29. Publication trends for patent families grouped into the category of Trematodes

The earliest representative family member was a foreign patent issued in 1982. The second place
document was published two years later in 1984. Patent publication spiked in the early 1990’searly 2000’s and again starting around 2010. One-hundred patent family representatives were
published in both 2011 and 2012. There has been nothing published for 2013, yet.

Top IPC (Current) Classifications
The International Patent Classification (IPC) system, established in 1971, is administrated by the
World Intellectual Property Organization (WIPO). The IPC “provides for a hierarchical system
of language independent symbols for the classification of patents and utility models according to
the different areas of technology to which they pertain.”138 The IPC contains eight core sections
with approximately 70,000 subdivisions, called advanced levels. WIPO continuously revises the
IPC, with the core levels being updated every three years and the advance levels being reviewed
a few times each year. The current version of the core levels was released in 2012.
The IPC (Current) codes were analyzed for each patent family. Some families had more than
one code, and each was counted. For the overall data set 15 codes represented 24 or more
138

World Intellectual Property Organization, Preface to the International Patent Classification (IPC), WIPO IP
SERVICES, http://www.wipo.int/classifications/ipc/en/general/preface.html (last visited Apr. 18, 2012).
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families. The top two codes were A61K 39/00 which contains medicinal preparations containing
antigens or antibodies and C07K 14/435 which contains organic compounds from humans and
from animals.. The definitions for the top 15 IPC families are provided in the table below.
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Figure 30. Top IPC (Current) Classification of the entire relevant dataset of 210 relevant families. Each class
represented at least 24 different families.
Table IX. Definitions of the Top IPC (Current) Classifications of Vaccine Documents.

A61K 39/00

123 Medicinal preparations containing antigens or antibodies

C07K 14/435

68 Chemistry:Organic Chemisry: From Animals or From Humans

A61K 48/00

Medicinal preparations containing genetic material which is
46 inserted into cells of the living body to treat genetic diseases
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A61P 33/12

37 Anti-parasitic agent: Schistosomicides

C07K 16/18

34

C12N 15/12

Mutation or Genetic engineering: Genes encoding animal
34 proteins

A61K 39/002

29 Medicinal Preparations containing Protozoa antigens

C12N 1/21

Micro-organism modified by introduction of foreign
27 genetic material

C12N 15/09

24 Mutation or genetic engineering: Recombinant DNA-technology

A61P 33/0

24 Antiparasitic agents

Immunoglobulins against material from animals or humans
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Conclusions
A search of the patent literature for publications containing keywords related to the helminth
vaccines returned approximately 2,700 total documents representing almost 447 patent families.
After examining the search results 210 of those patent documents related to the prophylactic
helminth vaccines or for technologies that are used in the manufacture of vaccines. Of those
relevant documents, approximately 13% are specifically related cestodes, 30% were related to
nematodes, 49% were related to cestodes with the remainder being non-specific. Thus, vaccine
and vaccine related technologies are predominantly focused on nematodes and trematodes. This
occurrence is not surprising as trematodes are highly prevalent in South-east Asian and
nematodes readily infect both humans as well as livestock.
However, filing of applications related to parasitic worms has been steadily increasing in the last
decade, so there are likely many new technological advances that have yet to be fully tested in
effectiveness against parasitic worms.
Helminth vaccine technologies appear to originate from a small set of countries, mostly the
United States, Great Britain, France, China, Brazil, Australia, and New Zealand. Protection for
helminth related intellectual property has been sought worldwide. However, except for Brazil
coverage in South America is quite minimal, and except for South Africa protection for these
technologies is sparse in Africa.
Top assignees for the relevant families were mostly large pharmaceutical companies,
with the majority of patent families coming from Heska, followed by Merck, Institut Pastuer,
AusBiotech, and Biotechnology and Biological Sciences Research Council.
Progress is being made towards the development of an effective vaccine against
helminthiases, but much work remains to be done, especially testing these novel vaccines under
clinical conditions. Additionally, this much-needed technology needs to be distributed to the
least-developed nations.
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Appendix Materials
APPENDIX A: Master Coding Spreadsheet (electronic version only).
This Excel file contains a series of spreadsheets related to the coding of the representative
documents from the 447 INPADOC family members found relevant from our searches. The first
sheet contains the 447 family members, the category they were coded into indicated by color,
and notes for the family members related to the basis of the coding decisions. The second, third,
fourth, and fifth and sixth sheets are divided by categories, cestodes, nematodes, trematodes,
nondistinguished and other. Each sheet contains the subcategories for each category and shows
the subcategory where each family member was placed.
Table 4. Indicating the color used for coding family members into specific categories
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APPENDIX B: Full Records of Relevant Family Members (electronic version only).
This Excel file contains detailed information of each of the 210 relevant patent family member.
The full records, containing all available information extracted from Thomson Innovation, are
given for each representative family member. Documents are organized alphabetically by
publication number.

APPENDIX C: Full Records of all Relevant Documents (electronic version only).
This Excel file has detailed information of each relevant patent document. The full records,
containing all available information extracted from Thomson Innovation, are given for each
document. Documents are organized alphabetically by publication number.
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APPENDIX D: Top Multi-Jurisdictional Filings Spreadsheet (electronic version only).
This Excel file has representative family members ranked according the size (number of
publications) of the INPADOC family each document represents. The top 21 largest families are
then analyzed based on the total number of jurisdictions in which each family has been filed.
Data is assembled from INPADOC, DWPI and TotalPatent family data.
APPENDIX E: Assignees Analysis Spreadsheet (electronic version only).
Assignee data for each representative family member was manually corrected to reflect changing
company names or the acquisition of an assignee by another company. This Excel file details
assignee data first by publication number, and then assignees are shown by total number of
families believed to be owned by that assignee. All relevant family members were pooled
together to generate an assignee list covering all highly relevant documents. The website for
each assignee is also given, if possible.
APPENDIX F: Priority Document Spreadsheet (electronic version only).
This Excel file has representative family members marked according to the earliest priority
document of each INPADOC family. Data is assembled from INPADOC, DWPI and TotalPatent
family data. The determinations is made from a combination of both TI’s recommendation as
well as by an analysis given by the team member examining the priority document.
Appendix G: PDF Files of Representative Patent Documents (electronic version only).
This folder contains the pdf files for each representative family member, if available. Note that in
a few instances a pdf file of the representative family member was not available. Thus these
folders do not contain the complete number of representative documents.
Appendix H: PDF Files of Selected Non-Patent Literature (electronic version only).
This folder contains pdf files for selected non-patent literature relevant to helminth vaccines. An
extensive search of NPL was not performed; rather the documents included in this folder are
mostly review articles which reveal the general state of the art, summarize available
technologies, or discuss strategic approaches to immunization.
Appendix I: Keywords Used in Searching.
The following represents the keywords used by the team members in patent database searching.
Note that each team member used different combinations of these terms, and only a subset of
terms was used for any particular search.
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List of parasites and keyword list
Tapeworms
Taenia multiceps
Diphyllobothrium latum
Echinococcus granulosus,
Echinococcus multilocularis,
E. vogeli,
E. oligarthrus
Hymenolepis nana,
Hymenolepis diminuta
Taenia saginata
Taenia solium
Bertiella mucronata,
Bertiella studeri
Spirometra erinaceieuropaei
Flukes
Clonorchis sinensis;
Clonorchis viverrini
Dicrocoelium dendriticum
Fasciola hepatica,
Fasciola gigantica
Fasciolopsis buski
Gnathostoma spinigerum
Gnathostoma hispidum
Metagonimus yokogawai
Opisthorchis viverrini,
Opisthorchis felineus,
Clonorchis sinensis
Paragonimus westermani;
Paragonimus africanus;
Paragonimus caliensis;
Paragonimus kellicotti
;Paragonimus skrjabini;
Paragonimus uterobilateralis
Schistosoma sp.
Schistosoma mansoni
Schistosoma haematobium
Schistosoma japonicum
Schistosoma mekongi Echinostoma echinatum
Trichobilharzia regenti,
Schistosomatidae
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Roundworm
Ancylostoma duodenale
Necator americanus
Angiostrongylus costaricensis
Anisakis
Ascaris sp.
Ascaris lumbricoides
Baylisascaris procyonis
Brugia malayi,
Brugia timori
Dioctophyme renale
Dracunculus medinensis
Enterobius vermicularis,
Enterobius gregorii
Loa loa filaria
Mansonella streptocerca
Onchocerca volvulus,
Onchocerciasis
Strongyloides stercoralis
Toxocara canis,
Toxocara cati
Trichinella spiralis,
Trichinella britovi,
Trichinella nelsoni,
Trichinella nativa
Wuchereria bancrofti
Trichuris trichiura,
Trichuris vulpis

•

•

Parasitic Worm
o (any genus/species above)
o Tapeworm
o Cestoda
o Ascaris
o Nematod!
o Helminth (mess with root extenders with this one)
o Schistosom*
o Endoparasit*
Combination of vaccine and parasitic worms
o Anthelminthic
o Anthelmintic
o Antihelminthic
o Antihelmintic
o !helmint!
o Vermifuge
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o
o
o
o
•

Vermicide
vermifugal
Anthelminth
Dehelminthisation (dehelminthization?)

Vaccine
o Immun! (TP) Immun* (TI)
o Immunologic! Immunologic*
o Immunostimul! or immuno-stimul!
o Immunomodul! or immuno-modul!
o Immunologentic
o Immunogen! Immunogen*
o Immuniz! Immuniz
o Vaccin! (TP) Vaccin* (TI)
o Virotherap! Virotherap*
o Prophyl! Prophyl*
o Antigen! Antigen*
! Epitope! Epitope*
! Determinant
o Antiinfective or anti-infective (sp?)
o Antiviral or anti-viral or anti viral
o Viricide or Virucide
o Prevent! Prevent*
o Phage
o PARASITICIDAL

Appendix J: Notes on Patent Families.
If there are several applications or publications for an individual invention (in other countries)
claiming the same priority or priorities and originating from the same inventors, those documents
constitute a “patent family.” All of the family members are related to one another by common
priority publications with associated priority dates. INPADOC families are organized solely on
priority data, whereas DWPI families focus on the inventions such that divisional applications of
a single priority document are considered to be in different patent families. Further, Lexis
TotalPatent reports “extended families” which are similar to INPADOC families but include
more jurisdictions.
The concept of the patent family first emerged through the Paris Convention on the Protection of
Intellectual Property in 1883, while automated systems enabling patent family searching became
available through the establishment of the IIB in The Hague in 1947and INPADOC in Vienna in
1972. Since then, patent searching has evolved due to exponential improvements in computing
and communication technology.
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The term patent family can be defined in a number of ways depending on the relationship
between a patent document and its priority or priorities within the meaning of the Paris
Convention. The differences only become obvious when the structure of a patent application is
complex, i.e. when applications are filed in several countries. Such applications may cite various
earlier applications as priorities, or the different patent offices involved in the grant process may
accept or refuse different patent claims. This results in patents which have different scopes of
protection.
An important point when using any database to retrieve information on patent families is that
there is never any guarantee that you will find all the corresponding patent documents that exist.
Database producers do what they can to ensure completeness, but they can never guarantee it.”139
The “Extended” (INPADOC) Patent Family
“The biobibliographic and legal status databases form the basis of the EPO’s raw data resources
(INPADOC). In February 2008 the bibliographic data included about 60 million bibliographic
data sets from almost 80 different countries. The legal status database contains a collection of
more than 50 million legal events from 48 countries.
From the beginning, the concept was to cover as many countries and as many publication levels
as possible. One of the strongest motives for the integration of INPADOC into the EPO was the
wish to combine the particular strengths of INPADOC with the EPO’s existing in-house
bibliographic database, “DOC-DB.”
Following integration of the two databases in the 1990s, the raw data behind both databases is
now the same. And since esp@cenet draws on the same pool of data as raw data resources
(INPADOC) and DOC-DB, it contains the same documentation.
However, the philosophy of the “extended” (INPADOC) patent family is quite different, and so
are the results of family searches. Unlike the “also published as” feature in esp@cenet, which
only shows “equivalents,” i.e. almost identical documents, an INPADOC family search should
retrieve all documents relating in any way to the root document.
Features of INPADOC
When using INPADOC via one of the commercial database host services, it bears all the
esp@cenet features, plus the following:

139

EUROPEAN PATENT OFFICE, Patent Families (Feb. 29, 2008), http://www.epo.org/patents/patentinformation/about/families.html.
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•
•
•
•

Standardization of applicant and inventor names
References to abstracts from Chemical Abstracts and Thomson Scientific
Abstracts are made within the patent family
By including the legal status database additional information is available and
additional family links can be established
National application numbers, international application numbers and domestic
relations are included in the family search

For both of the EPO’s raw data resources (INPADOC) and esp@cenet, even where no priority
has been claimed by the patent application, artificial or “intellectual” links are built in systematic
way for the complete PCT minimum documentation. The same is done for older documents
(pre-1968) for which the priority information is not complete.
Definition of the “extended” (INPADOC) patent family
All the documents directly or indirectly linked via a priority document belong to one patent
family. In the case shown below, documents D1 to D5 belong to the same patent family, P1.

FAMILY P1
Document D1
Document D2
Document D3
Document D4
Document D5

Priority P1
Priority P1
Priority P1

Priority P2
Priority P2
Priority P2

Priority P3
Priority P5

As mentioned above, national patent application numbers, international application numbers and
domestic relations are included in the family search.
In the “extended” (INPADOC) patent family, it does not matter where a search is started. It can
be an application number, a priority application number or a publication number.
If the search starts with a publication number, all application numbers, domestic application
numbers, priority numbers and international application numbers are used to retrieve additional
documents. For all documents found in this step, step one is repeated. This iteration process
ends only when no more new documents can be found.
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Raw data resources (INPADOC) also use some additional sophisticated rules for certain
countries, for example, if publication numbers are used instead of priority numbers in the
original documents. This happened rather frequently for older documents, where the priority
claims were not treated as carefully as they are now. The inclusion of legal status information in
the patent search also sometimes retrieves additional links, e.g. for divisional applications,
continuations, continuations in part or national publications of first filings of PCT (international)
applications, where the priority links are often missing.
Limitations of the family search in raw data resources (INPADOC) have to rely on the
correctness of the data supplied by the co-operating patent offices and the extent to which it is up
to date. In particular, delays in the delivery of bibliographic data can vary significantly
depending on the country concerned and the time period covered. Before relying on the
completeness of a patent family, users should check where there are gaps or delays in certain
areas. This kind of information can be found in the PFS and PRS statistics on the internet, which
are updated weekly and contain indications of missing or delayed document series. See raw data
resources (INPADOC) useful tables and statistics. To be absolutely sure about the actual status
of a patent, users are recommended to contact the appropriate patent issuing authority direct.
Particular care has to be taken in the case of European patents which have entered into the
national phase. The completeness and accuracy of data can vary significantly from country to
country. A good overview of the volume and kind of "post-grant" information available in raw
data resources (INPADOC) can be found in the raw data resources (INPADOC) FAQ. For most
of the EPO member states, information about the validation, lapse, etc., of European patents is
given as part of the legal status information, and as mentioned before is less consistent due to the
different quality of data available. Starting from week 50/2007, additional post-grant
information is taken from the fee administration system and included in the legal status part of
the database.
Thomson Scientific WPI Patent Family (DWPI)
“Patent Families in the Thomson Scientific World Patents Index (WPI) draw together patents
covering the same invention. Their relationship is defined by the priority or application details
claimed by each document. Thus, in its simplest form, a new document (D1) claiming a unique
priority (P1) will be assigned to be the basis of its own, new patent family in Thomson Scientific
WPI.
Subsequently, if a second document (D2) also claiming priority P1 is received by Thomson
Scientific this will be added (as an ―equivalentǁ‖) to the patent family already containing
document D1. Other documents claiming priority P1 will also be added to this family as
―equivalents as they are included in the database. Thus, a patent family may contain anything

96

from a single document to 10 or more. Each patent family represents a single record in the
Thomson Scientific WPI database.
The basic document is the first member of a patent family that appears in Thomson Scientific
WPI, so it may not necessarily be the first one published for that invention. Differences in the
speed that patenting authorities supply data to Thomson Scientific and in the processing time for
documents from different countries may affect which document appears in Thomson Scientific
WPI first and becomes basic.
Patents often claim more than a single priority and these must match before any equivalent is
added to a family. This means that if a basic document (D3) claims priorities P2, P3 & P4, a
subsequent document (D4) claiming priorities P2 & P3 will be added to the family as an
equivalent, whereas patent D5 which claims priorities P2, P3 and a unique priority (P5) will form
the basis of a new, but related patent family. In cases such as this, the accession number of any
related family is included in the cross-reference field of each relevant Thomson Scientific WPI
record.
Divisions and continuation patents maintain the same status as the original specification. This
means that if GB1 is a basic, and GB2 is divisional to GB1, then GB2 will also be a basic (in its
own family). However, if GB1 is equivalent to another document already in the Thomson
Scientific WPI database, then GB2 will also join this family as an equivalent. It should be noted
that family relationships will be defined by the order in which patents appear in Thomson
Scientific WPI.
Thomson Scientific also puts a lot of resources into including patents in families even when no
foreign priority is claimed, e.g. when an application has been made beyond the 12 months
defined by the Paris Convention. Thomson Scientific identifies these "non-convention"
equivalents by the presence of foreign nationals and addresses in the Inventor field in the
absence of priority data other than the local filing details. Equivalency is determined through a
time-consuming manual check of inventors, subject matter, etc.
In this way Thomson Scientific attempts to make patent families in Thomson Scientific PI as
comprehensive as possible. However, because of the incidence of multiple priorities, and patent
divisions and continuations (especially continuing applications in US documents), it is important
to retrieve all related families through their common priorities in order to have a comprehensive
overview of patent family relationships.”140

140

Id.
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Appendix K: PDF Files of This Report (electronic version only).
This folder contains separate pdf files of this report and the cover to the report. The ITTI Clinic
wishes for this report to be as widely disseminated as possible, so that all interested parties may
have access to the information presented herein. However, anyone is free to base a subsequent
report on our work as long as proper attribution is given to ITTI.
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